[
  {
    "id": "41540706",
    "title_en": "[Sulforaphane reduces reactive astrocyte-mediated neuron apoptosis <i>in vitro</i> by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes].",
    "pub_date": "2026 Jan",
    "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
    "abstract_en": "To explore the effects of sulforaphane (SFN) on AÎ²42-activated U87 astrocyte-mediated apoptosis of SH-SY5Y neurons <i>in vitro</i>. U87 cells treated with different concentrations of AÎ²42, SFN or both were examined for changes in cell activity, IL-6 and TNF-Î± mRNA expression, release of IL-6 and TNF-Î± proteins, and expressions of p-p38, p-p65 and GFAP using CCK-8 assay, RT-qPCR, ELISA and Western blotting. SH-SY5Y neurons were co-cultured with U87 astrocytes treated with AÎ²42 alone or in combination with SFN or SB203580 for 24 h, and the changes in Bax protein expression levels and viability of SH-SY5Y cells were examined. The effects of AÎ²42, SFN, and their combination were also observed in astrocytes isolated from mouse brain tissues, and the indirect effects of astrocyte treatmentt on viability of the co-cultured primary neurons were assessed. The viability of U87 astrocytes increased significantly following treatment with 1.25 Î¼mol/L AÎ²42 but decreased after AÎ²42 treatment above 5 Î¼mol/L. SFN treatments for 24 h below 5 Î¼mol/L did not significantly affect U87 cell viability. AÎ²42 treatment significantly increased protein expressions of p-p38, p-p65 and GFAP, mRNA expression levels of IL-6 and TNF-Î±, and IL-6 and TNF-Î± levels in culture supernatant of U87 cells. SH-SY5Y cells co-cultured with AÎ²42-treated U87 cells showed significantly increased protein expressions of Bax, and exhibited lowered viability following co-culture with 5 Î¼mol/L AÎ²42-treated U87 cells. The isolated mouse astrocytes showed lowered viability following AÎ²42 treatment above 10 Î¼mol/L, but SFN treatment below 5 Î¼mol/L for 24 did not obviously affect the cell viability. The primary neurons co-cultured with AÎ²42-treated mouse astrocytes showed significantly lower cell viability than those co-cultured with the astrocytes treated with AÎ²+SFN or AÎ²+SB203580. SFN attenuates astrocyte-mediated neuron apoptosis by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›å°‘ç”±é˜¿èŒ²æµ·é»˜ç—‡ç›¸é—œè›‹ç™½è³ªAÎ²42å¼•èµ·çš„ç¥ç¶“ç´°èƒæ­»äº¡æœ‰ä¸€å®šçš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½å°å¤§è…¦å¥åº·æœ‰æ‰€å¹«åŠ©ï¼Œé€²è€Œé™ä½æŸäº›ç¥ç¶“ç–¾ç—…çš„é¢¨éšªã€‚é›–ç„¶é€™äº›çµæœé‚„éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªï¼Œä½†å®ƒå€‘ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿå»ºè­°æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é˜¿èŒ²æµ·é»˜ç—‡ç›¸é—œçš„AÎ²42è›‹ç™½è³ªæ‰€å¼•ç™¼çš„ç¥ç¶“ç´°èƒå‡‹äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨é˜¿èŒ²æµ·é»˜ç—‡çš„ç—…ç†æ©Ÿåˆ¶ï¼Œå°¤å…¶æ˜¯å¦‚ä½•é€éèª¿ç¯€ç¥ç¶“è† è³ªç´°èƒçš„æ´»å‹•ä¾†å½±éŸ¿ç¥ç¶“å…ƒçš„å­˜æ´»ã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£é˜¿èŒ²æµ·é»˜ç—‡çš„ç™¼å±•ï¼Œä¹Ÿå¯èƒ½ç‚ºæ²»ç™‚ç­–ç•¥çš„åˆ¶å®šæä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡çš„U87ç¥ç¶“è† è³ªç´°èƒå’ŒSH-SY5Yç¥ç¶“å…ƒé€²è¡Œäº†ç´°èƒå…±åŸ¹é¤Šã€‚ä»–å€‘å°‡U87ç´°èƒæš´éœ²æ–¼ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿç´°èƒæ´»æ€§åŠç›¸é—œè›‹ç™½è³ªå’ŒåŸºå› è¡¨é”çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„å¾å°é¼ è…¦çµ„ç¹”ä¸­åˆ†é›¢å‡ºç¥ç¶“è† è³ªç´°èƒï¼Œé€²è¡Œäº†é¡ä¼¼çš„è™•ç†ï¼Œä»¥è©•ä¼°é€™äº›ç´°èƒå°ç¥ç¶“å…ƒå­˜æ´»çš„é–“æ¥å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶U87ç´°èƒæ¥å—1.25 Î¼mol/Lçš„AÎ²42è™•ç†æ™‚ï¼Œå…¶ç´°èƒæ´»æ€§é¡¯è‘—å¢åŠ ï¼Œä½†ç•¶æ¿ƒåº¦è¶…é5 Î¼mol/Læ™‚ï¼Œç´°èƒæ´»æ€§å‰‡ä¸‹é™ã€‚è˜¿è””ç¡«ç´ åœ¨ä½æ–¼5 Î¼mol/Lçš„æ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œèˆ‡AÎ²42è™•ç†çš„U87ç´°èƒå…±åŸ¹é¤Šçš„SH-SY5Yç¥ç¶“å…ƒé¡¯ç¤ºå‡ºBaxè›‹ç™½è¡¨é”å¢åŠ ï¼Œä¸”ç´°èƒæ´»æ€§é™ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶MAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘ç¥ç¶“è† è³ªç´°èƒä»‹å°çš„ç¥ç¶“å…ƒå‡‹äº¡ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„ç·šç´¢ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›å°‘ç”±é˜¿èŒ²æµ·é»˜ç—‡ç›¸é—œè›‹ç™½è³ªAÎ²42å¼•èµ·çš„ç¥ç¶“ç´°èƒæ­»äº¡æœ‰ä¸€å®šçš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½å°å¤§è…¦å¥åº·æœ‰æ‰€å¹«åŠ©ï¼Œé€²è€Œé™ä½æŸäº›ç¥ç¶“ç–¾ç—…çš„é¢¨éšªã€‚é›–ç„¶é€™äº›çµæœé‚„éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªï¼Œä½†å®ƒå€‘ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿå»ºè­°æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é˜¿èŒ²æµ·é»˜ç—‡ç›¸é—œçš„AÎ²42è›‹ç™½è³ªæ‰€å¼•ç™¼çš„ç¥ç¶“ç´°èƒå‡‹äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨é˜¿èŒ²æµ·é»˜ç—‡çš„ç—…ç†æ©Ÿåˆ¶ï¼Œå°¤å…¶æ˜¯å¦‚ä½•é€éèª¿ç¯€ç¥ç¶“è† è³ªç´°èƒçš„æ´»å‹•ä¾†å½±éŸ¿ç¥ç¶“å…ƒçš„å­˜æ´»ã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£é˜¿èŒ²æµ·é»˜ç—‡çš„ç™¼å±•ï¼Œä¹Ÿå¯èƒ½ç‚ºæ²»ç™‚ç­–ç•¥çš„åˆ¶å®šæä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡çš„U87ç¥ç¶“è† è³ªç´°èƒå’ŒSH-SY5Yç¥ç¶“å…ƒé€²è¡Œäº†ç´°èƒå…±åŸ¹é¤Šã€‚ä»–å€‘å°‡U87ç´°èƒæš´éœ²æ–¼ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿç´°èƒæ´»æ€§åŠç›¸é—œè›‹ç™½è³ªå’ŒåŸºå› è¡¨é”çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„å¾å°é¼ è…¦çµ„ç¹”ä¸­åˆ†é›¢å‡ºç¥ç¶“è† è³ªç´°èƒï¼Œé€²è¡Œäº†é¡ä¼¼çš„è™•ç†ï¼Œä»¥è©•ä¼°é€™äº›ç´°èƒå°ç¥ç¶“å…ƒå­˜æ´»çš„é–“æ¥å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶U87ç´°èƒæ¥å—1.25 Î¼mol/Lçš„AÎ²42è™•ç†æ™‚ï¼Œå…¶ç´°èƒæ´»æ€§é¡¯è‘—å¢åŠ ï¼Œä½†ç•¶æ¿ƒåº¦è¶…é5 Î¼mol/Læ™‚ï¼Œç´°èƒæ´»æ€§å‰‡ä¸‹é™ã€‚è˜¿è””ç¡«ç´ åœ¨ä½æ–¼5 Î¼mol/Lçš„æ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œèˆ‡AÎ²42è™•ç†çš„U87ç´°èƒå…±åŸ¹é¤Šçš„SH-SY5Yç¥ç¶“å…ƒé¡¯ç¤ºå‡ºBaxè›‹ç™½è¡¨é”å¢åŠ ï¼Œä¸”ç´°èƒæ´»æ€§é™ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶MAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘ç¥ç¶“è† è³ªç´°èƒä»‹å°çš„ç¥ç¶“å…ƒå‡‹äº¡ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„ç·šç´¢ã€‚",
    "fb_post": "æ ¹æ“šã€ŠNan fang yi ke da xue xue bao = Journal of Southern Medical Universityã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœä¸åªè®“æˆ‘å€‘çš„èº«é«”æ›´å¥åº·ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¤§è…¦æœ‰å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆå­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰é£Ÿç‰©ä¸­ï¼‰å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é˜¿èŒ²æµ·é»˜ç—‡ç›¸é—œçš„ç¥ç¶“ç´°èƒæ­»äº¡ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®å«åšAÎ²42çš„è›‹ç™½è³ªï¼Œé€™ç¨®è›‹ç™½è³ªèˆ‡é˜¿èŒ²æµ·é»˜ç—‡æœ‰é—œã€‚\n\nç ”ç©¶äººå“¡ç”¨äººé¡çš„ç¥ç¶“ç´°èƒå’Œå°é¼ çš„è…¦ç´°èƒé€²è¡Œå¯¦é©—ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶ç´°èƒæ¥è§¸åˆ°é©é‡çš„AÎ²42æ™‚ï¼Œç´°èƒæ´»æ€§æœƒå¢åŠ ï¼Œä½†å¦‚æœæ¿ƒåº¦éé«˜ï¼Œç´°èƒæ´»æ€§å°±æœƒä¸‹é™ã€‚è€Œè˜¿è””ç¡«ç´ åœ¨ä½æ¿ƒåº¦ä¸‹å°ç´°èƒçš„å½±éŸ¿ä¸å¤§ï¼Œä½†å®ƒå¯èƒ½é€éæŸäº›ä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘ç¥ç¶“ç´°èƒçš„æ­»äº¡ã€‚\n\né€™äº›ç™¼ç¾é›–ç„¶é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªï¼Œä½†å®ƒå€‘ç‚ºæˆ‘å€‘çš„é£²é£Ÿæä¾›äº†æ–°çš„æ€è·¯ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å¤§è…¦å¥åº·ã€‚\n2. é©é‡çš„AÎ²42å°ç´°èƒæ´»æ€§æœ‰å½±éŸ¿ã€‚\n3. é€²ä¸€æ­¥çš„ç ”ç©¶å°‡æœ‰åŠ©æ–¼ç†è§£é˜¿èŒ²æµ·é»˜ç—‡çš„ç™¼å±•ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experiment and main findings of a study on sulforaphane. Include simple illustrations of broccoli or sulforaphane symbols, simplified representations of human and animal cells, and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' that highlights protective effects and changes observed in the experiment.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é˜¿èŒ²æµ·é»˜ç—‡ Alzheimer's Disease",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41540706/"
  },
  {
    "id": "41535692",
    "title_en": "Inhibiting autophagy enhances anti-cancer properties of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Scientific reports",
    "abstract_en": "Bladder cancer (BC) has an extremely low survival rate due to its tendency to metastasize. The antimalarial drug chloroquine (CQ) can inhibit BC progression and invasiveness by targeting basal autophagy. However, the mechanism by which CQ affects BC is not defined. Here, we revealed that although CQ showed an anticancer effect by reducing the migration and proliferation of the analyzed bladder cancer cells, it increased the expression of ICAM-1, a protein whose expression is associated with higher tumorigenic potential. Sulforaphane (SFN), a well-known ICAM-1 inhibitor, significantly contributed to the enhancement of anticancer effect of CQ, through regulation of both AKT/GSK-3Î² and mTOR/ULK pathways, which led to effective inhibition of autophagy, reduced proliferation level or inhibition of migration of the analyzed bladder cells. Moreover, regulation of pathways related to autophagy contributed to the reduction of mitochondrial membrane potential and regulation of ROS level. Nevertheless, the level of influence of CQ and SFN on the anticancer effects strongly depended on the molecular basis of the analyzed bladder cell lines. Our data indicate that although CQ exerts antitumor effects on bladder cancer cells, it should be noted that activation of some pro-tumor pathways may be associated with subsequent disease relapse or treatment resistance.",
    "para1": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è†€èƒ±ç™Œçš„æ²»ç™‚ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯èƒ½åœ¨æŠ‘åˆ¶ç™Œç´°èƒçš„åŒæ™‚ï¼Œå»ä¹Ÿå¯èƒ½ä¿ƒé€²æŸäº›èˆ‡è…«ç˜¤ç™¼å±•ç›¸é—œçš„è›‹ç™½è³ªè¡¨é”ã€‚å› æ­¤ï¼Œåœ¨ä½¿ç”¨é€™äº›è—¥ç‰©æ™‚ï¼Œäº†è§£å®ƒå€‘çš„ä½œç”¨æ©Ÿåˆ¶éå¸¸é‡è¦ï¼Œä»¥é¿å…å¯èƒ½çš„å‰¯ä½œç”¨å’Œæ²»ç™‚å¤±æ•—çš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶æ°¯å–¹åœ¨æŸäº›æƒ…æ³ä¸‹é¡¯ç¤ºå‡ºæŠ—ç™Œæ•ˆæœï¼Œä½†å®ƒæ˜¯å¦æœƒåŒæ™‚æ¿€æ´»ä¸€äº›å¯èƒ½ä¿ƒé€²è…«ç˜¤ç™¼å±•çš„é€”å¾‘ï¼Œé€™å°æ–¼è†€èƒ±ç™Œçš„æ²»ç™‚æœ‰ä½•å½±éŸ¿ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰çš„è¯åˆä½¿ç”¨å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡ç´°èƒçš„é·ç§»å’Œå¢æ®–æƒ…æ³ï¼Œä»¥åŠè©•ä¼°èˆ‡è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯çš„è®ŠåŒ–ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºé€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦äº†è§£å®ƒå€‘å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹èƒ½å¤ æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†åŒæ™‚ä¹Ÿæœƒå¢åŠ ICAM-1é€™ç¨®èˆ‡è…«ç˜¤æ½›åŠ›ç›¸é—œçš„è›‹ç™½è³ªçš„è¡¨é”ã€‚è˜¿è””ç¡«ç´ å‰‡èƒ½é¡¯è‘—å¢å¼·æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œé€éèª¿æ§å¤šæ¢ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‡ªå™¬å’Œç™Œç´°èƒçš„å¢æ®–ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹ŸæŒ‡å‡ºï¼Œé€™äº›è—¥ç‰©çš„æ•ˆæœæœƒå—åˆ°ä¸åŒè†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤å½±éŸ¿ï¼Œå› æ­¤åœ¨è‡¨åºŠæ‡‰ç”¨æ™‚éœ€è¬¹æ…è€ƒé‡ã€‚",
    "explanation_zh": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è†€èƒ±ç™Œçš„æ²»ç™‚ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯èƒ½åœ¨æŠ‘åˆ¶ç™Œç´°èƒçš„åŒæ™‚ï¼Œå»ä¹Ÿå¯èƒ½ä¿ƒé€²æŸäº›èˆ‡è…«ç˜¤ç™¼å±•ç›¸é—œçš„è›‹ç™½è³ªè¡¨é”ã€‚å› æ­¤ï¼Œåœ¨ä½¿ç”¨é€™äº›è—¥ç‰©æ™‚ï¼Œäº†è§£å®ƒå€‘çš„ä½œç”¨æ©Ÿåˆ¶éå¸¸é‡è¦ï¼Œä»¥é¿å…å¯èƒ½çš„å‰¯ä½œç”¨å’Œæ²»ç™‚å¤±æ•—çš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶æ°¯å–¹åœ¨æŸäº›æƒ…æ³ä¸‹é¡¯ç¤ºå‡ºæŠ—ç™Œæ•ˆæœï¼Œä½†å®ƒæ˜¯å¦æœƒåŒæ™‚æ¿€æ´»ä¸€äº›å¯èƒ½ä¿ƒé€²è…«ç˜¤ç™¼å±•çš„é€”å¾‘ï¼Œé€™å°æ–¼è†€èƒ±ç™Œçš„æ²»ç™‚æœ‰ä½•å½±éŸ¿ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰çš„è¯åˆä½¿ç”¨å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡ç´°èƒçš„é·ç§»å’Œå¢æ®–æƒ…æ³ï¼Œä»¥åŠè©•ä¼°èˆ‡è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯çš„è®ŠåŒ–ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºé€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦äº†è§£å®ƒå€‘å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹èƒ½å¤ æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†åŒæ™‚ä¹Ÿæœƒå¢åŠ ICAM-1é€™ç¨®èˆ‡è…«ç˜¤æ½›åŠ›ç›¸é—œçš„è›‹ç™½è³ªçš„è¡¨é”ã€‚è˜¿è””ç¡«ç´ å‰‡èƒ½é¡¯è‘—å¢å¼·æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œé€éèª¿æ§å¤šæ¢ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‡ªå™¬å’Œç™Œç´°èƒçš„å¢æ®–ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹ŸæŒ‡å‡ºï¼Œé€™äº›è—¥ç‰©çš„æ•ˆæœæœƒå—åˆ°ä¸åŒè†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤å½±éŸ¿ï¼Œå› æ­¤åœ¨è‡¨åºŠæ‡‰ç”¨æ™‚éœ€è¬¹æ…è€ƒé‡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠScientific reportsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ å¤§å®¶çŸ¥é“å—ï¼Ÿè†€èƒ±ç™Œæ˜¯ä¸€ç¨®ç›¸å°é›£ä»¥å°ä»˜çš„ç™Œç—‡ï¼Œå­˜æ´»ç‡ä¸é«˜ï¼Œå› ç‚ºå®ƒå¸¸å¸¸æœƒè½‰ç§»ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°é€™å€‹å•é¡Œæœ‰äº†æ–°çš„æ€è€ƒï¼ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼ä¸€ç¨®æŠ—ç˜§ç–¾è—¥ç‰©å«åšæ°¯å–¹ï¼ˆCQï¼‰ï¼Œæƒ³çœ‹çœ‹å®ƒå°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ã€‚é›–ç„¶æ°¯å–¹åœ¨æŸäº›æƒ…æ³ä¸‹èƒ½æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä½†ç ”ç©¶è€…ä¹Ÿæ“”å¿ƒå®ƒå¯èƒ½æœƒæ¿€æ´»ä¸€äº›ä¸å¥½çš„é€”å¾‘ï¼Œå½±éŸ¿æ²»ç™‚æ•ˆæœã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒï¼Œæ¸¬é‡äº†æ°¯å–¹å’Œä¸€ç¨®å«è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰çš„ç‰©è³ªè¯åˆä½¿ç”¨çš„æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œæ°¯å–¹èƒ½æ¸›å°‘ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†å»æœƒå¢åŠ ä¸€ç¨®èˆ‡è…«ç˜¤ç™¼å±•æœ‰é—œçš„è›‹ç™½è³ªè¡¨é”ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡èƒ½å¼·åŒ–æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œå¹«åŠ©æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–ã€‚  \n\nä¸éï¼Œé€™äº›è—¥ç‰©çš„æ•ˆæœæœƒå› ä¸åŒçš„è†€èƒ±ç™Œç´°èƒè€Œæœ‰æ‰€ä¸åŒï¼Œæ‰€ä»¥åœ¨è‡¨åºŠæ‡‰ç”¨ä¸Šé‚„éœ€è¦è¬¹æ…è€ƒé‡ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. æ°¯å–¹èƒ½æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„å¢æ®–ï¼Œä½†æœ‰å¯èƒ½å¢åŠ è…«ç˜¤ç›¸é—œè›‹ç™½è³ªã€‚  \n2. è˜¿è””ç¡«ç´ å¯ä»¥å¢å¼·æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœã€‚  \n3. è—¥ç‰©æ•ˆæœæœƒå—åˆ°ç´°èƒé¡å‹çš„å½±éŸ¿ï¼Œéœ€è¬¹æ…ä½¿ç”¨ã€‚",
    "image_prompt": "Create a simple and informative illustration that explains the experimental methods and main findings of a study on the effects of chloroquine and sulforaphane on bladder cancer cells. The illustration should have a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified representations of experimental subjects like cells or humans, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è†€èƒ±ç™Œ Bladder Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41535692/"
  },
  {
    "id": "41511787",
    "title_en": "Sulforaphane attenuates DSS-induced ulcerative colitis <i>via</i> the Nrf2/STAT3 signaling pathway and gut microbiota modulation.",
    "pub_date": "2026 Jan",
    "journal": "Food & function",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables. Our previous studies have shown that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and signal transducer and activator of transcription 3 (STAT3) may play roles in the protective effects of SFN against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. This study aims to elucidate the underlying mechanisms. GEO database analysis revealed that <i>Nrf2</i> expression was reduced, while <i>STAT3</i> expression was elevated in the colonic mucosa of UC patients compared to healthy controls (<i>P</i> < 0.01). In the DSS-induced Caco-2 cell model, <i>Nrf2</i> siRNA transfection abolished the effects of SFN on enhancing Nrf2 and tight junction protein expression, suppressing inflammatory factors and reducing the phosphorylated-STAT3/STAT3 ratio. In DSS-induced UC mice, SFN alleviated colitic symptoms in wide-type mice, including weight loss, colon edema and shortening, and inflammatory cell infiltration. SFN also reduced the levels of inflammatory cytokines and enhanced tight junction protein expression in wide-type mice with colitis. However, these protective effects were largely abolished in Nrf2 knockout mice. Moreover, in Nrf2 knockout colitis mice, SFN reduced the gut microbial diversity and decreased the relative abundance of <i>Firmicutes</i> at the phylum level, as well as <i>Muribaculaceae</i> and <i>Lachnospiraceae</i>_NK4A136 at the genus level. In conclusion, the protective effects of SFN against UC may involve the regulation of the Nrf2/STAT3 signaling pathway and modulation of the gut microbiota, highlighting Nrf2 as a key mediator of SFN's action.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ–°è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„é˜²æ²»ä¸Šã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¹ç—›ã€è…¹ç€‰å’Œé«”é‡æ¸›è¼•ç­‰ç—‡ç‹€ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é™ä½æ½°ç˜æ€§çµè…¸ç‚çš„é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œç‚ºä»€éº¼è˜¿è””ç¡«ç´ èƒ½å¤ å°æŠ—ç”±ç¡«é…¸è‘¡èšç³–éˆ‰å¼•èµ·çš„æ½°ç˜æ€§çµè…¸ç‚ï¼Œä¸¦å¸Œæœ›æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€éåˆ†ææ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç ”ç©¶è€…ç™¼ç¾èˆ‡å¥åº·å°ç…§çµ„ç›¸æ¯”ï¼ŒæŸäº›é—œéµè›‹ç™½çš„è¡¨é”ç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé€™å¯èƒ½èˆ‡ç–¾ç—…çš„ç™¼å±•æœ‰é—œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†é€²è¡Œç ”ç©¶ã€‚é¦–å…ˆï¼Œä»–å€‘åˆ©ç”¨ç¡«é…¸è‘¡èšç³–éˆ‰èª˜å°å°é¼ ç”¢ç”Ÿæ½°ç˜æ€§çµè…¸ç‚ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œç ”ç©¶è€…ä¹Ÿåœ¨Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œé€šéè½‰æŸ“å°RNAä¾†ç ”ç©¶Nrf2çš„ä½œç”¨ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ä»–å€‘äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“çš„ç‚ç—‡åæ‡‰åŠå…¶ç›¸é—œçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•å’Œè…¸é“è…«è„¹ç­‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç‚ç—‡å› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·ä½œç”¨åœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å½±éŸ¿äº†è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥å½±éŸ¿è…¸é“å¥åº·ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ–°è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„é˜²æ²»ä¸Šã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¹ç—›ã€è…¹ç€‰å’Œé«”é‡æ¸›è¼•ç­‰ç—‡ç‹€ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é™ä½æ½°ç˜æ€§çµè…¸ç‚çš„é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œç‚ºä»€éº¼è˜¿è””ç¡«ç´ èƒ½å¤ å°æŠ—ç”±ç¡«é…¸è‘¡èšç³–éˆ‰å¼•èµ·çš„æ½°ç˜æ€§çµè…¸ç‚ï¼Œä¸¦å¸Œæœ›æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€éåˆ†ææ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç ”ç©¶è€…ç™¼ç¾èˆ‡å¥åº·å°ç…§çµ„ç›¸æ¯”ï¼ŒæŸäº›é—œéµè›‹ç™½çš„è¡¨é”ç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé€™å¯èƒ½èˆ‡ç–¾ç—…çš„ç™¼å±•æœ‰é—œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†é€²è¡Œç ”ç©¶ã€‚é¦–å…ˆï¼Œä»–å€‘åˆ©ç”¨ç¡«é…¸è‘¡èšç³–éˆ‰èª˜å°å°é¼ ç”¢ç”Ÿæ½°ç˜æ€§çµè…¸ç‚ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œç ”ç©¶è€…ä¹Ÿåœ¨Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œé€šéè½‰æŸ“å°RNAä¾†ç ”ç©¶Nrf2çš„ä½œç”¨ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ä»–å€‘äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“çš„ç‚ç—‡åæ‡‰åŠå…¶ç›¸é—œçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•å’Œè…¸é“è…«è„¹ç­‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç‚ç—‡å› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·ä½œç”¨åœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å½±éŸ¿äº†è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™å¯èƒ½é€²ä¸€æ­¥å½±éŸ¿è…¸é“å¥åº·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood & functionã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†ï¼Œå¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚æœ‰æ­£é¢çš„å½±éŸ¿ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®è®“äººæ„Ÿåˆ°ä¸é©çš„è…¸é“ç–¾ç—…ï¼Œæœƒé€ æˆè…¹ç—›å’Œè…¹ç€‰ç­‰ç—‡ç‹€ã€‚  \n  \né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ ç‚ºä»€éº¼èƒ½å¹«åŠ©å°æŠ—é€™ç¨®ç–¾ç—…ã€‚ä»–å€‘ä½¿ç”¨å°é¼ å’Œç´°èƒæ¨¡å‹é€²è¡Œå¯¦é©—ï¼Œç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ¸›è¼•å°é¼ çš„ç—‡ç‹€ï¼Œä¸¦é™ä½è…¸é“çš„ç‚ç—‡ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œé€™äº›æ•ˆæœä¼¼ä¹èˆ‡ä¸€ç¨®å«åšNrf2çš„è›‹ç™½è³ªæœ‰é—œï¼Œé€™å€‹è›‹ç™½è³ªåœ¨ä¿è­·è…¸é“å¥åº·ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚  \n  \nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚  \n2. å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½æ”¹å–„è…¸é“å¥åº·ã€‚  \n3. Nrf2è›‹ç™½è³ªåœ¨é€™å€‹éç¨‹ä¸­éå¸¸é—œéµï¼  \n  \nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨è…¸é“å¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹ï¼",
    "image_prompt": "Create a flat design infographic on the effects of sulforaphane on ulcerative colitis. Include simplified illustrations of broccoli and sulforaphane as symbols. Show simplified representations of experimental subjects like mice and cells. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Key Results' highlighting protective effects and changes observed. Use a white or light-colored background with soft colors for a scientific and informative style.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41511787/"
  },
  {
    "id": "41543290",
    "title_en": "Elucidation of Sulforaphane-Mediated Effects on the Cellular Human Metabolome Using Metabolic Profiling.",
    "pub_date": "2026 Jan",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from glucoraphanin, which occurs in broccoli. Several human health-promoting effects are attributed to the consumption of cruciferous vegetables or food supplements containing SFN. Its described cancer-preventive, chemoprotective, and antioxidant properties made SFN an increasingly important research topic. The antioxidant properties have previously been connected to stimulation of the Nuclear factor erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway. However, the global effects of SFN on the primary metabolic pathways have yet to be fully unraveled. Therefore metabolic profiling was used to elucidate the effects of SFN on the cellular metabolome. For this purpose, human hepatoblastoma cells (HepG2) were incubated with SFN and the changes of primary metabolite levels were determined by targeted hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC-MS/MS) analysis. Metabolic profiling revealed that SFN affects the tricarboxylic acid cycle, the urea cycle and their related amino acids. Furthermore, effects on glycolysis, pentose phosphate pathway and glutathione (GSH) levels were observed. This profound impact on nearly all primary metabolic pathways indicates a high bioactive potential of this natural compound. Especially elevated GSH levels underline the commonly described antioxidant potential of SFN.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰å¤šç¨®å¥½è™•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé£Ÿç”¨å«æœ‰è˜¿è””ç¡«ç´ çš„åå­—èŠ±ç§‘è”¬èœæˆ–è£œå……åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²ç™Œç—‡ã€ä¿è­·ç´°èƒå…å—æå‚·ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–çš„ç‰¹æ€§ã€‚é€™äº›ç‰¹æ€§ä½¿å¾—è˜¿è””ç¡«ç´ æˆç‚ºä¸€å€‹é‡è¦çš„ç ”ç©¶ä¸»é¡Œï¼Œå°¤å…¶æ˜¯åœ¨å°‹æ‰¾æœ‰æ•ˆçš„ç–¾ç—…é é˜²æ–¹æ³•æ–¹é¢ï¼Œå¯èƒ½ç‚ºæˆ‘å€‘æä¾›æ–°çš„æ€è·¯å’Œæ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¸»è¦ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æŠ—æ°§åŒ–å’Œç™Œç—‡é é˜²æ–¹é¢çš„æ½›åŠ›ã€‚å„˜ç®¡éå»çš„ç ”ç©¶å·²ç¶“æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä½†å°å…¶åœ¨ç´°èƒä»£è¬å±¤é¢çš„å…¨é¢å½±éŸ¿ä»ç„¶ä¸å¤ æ¸…æ¥šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€ç©ºç™½ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠåˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§äº’å‹•æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•ä½¿ç ”ç©¶è€…èƒ½å¤ è©³ç´°äº†è§£è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å…·é«”å½±éŸ¿ï¼Œä¸¦æ¢ç´¢å…¶åœ¨ä¸åŒä»£è¬é€”å¾‘ä¸­çš„ä½œç”¨ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘å’Œè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å…¶æå‡GSHæ°´å¹³çš„èƒ½åŠ›ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†å…¶æŠ—æ°§åŒ–ç‰¹æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰å¤šç¨®å¥½è™•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé£Ÿç”¨å«æœ‰è˜¿è””ç¡«ç´ çš„åå­—èŠ±ç§‘è”¬èœæˆ–è£œå……åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²ç™Œç—‡ã€ä¿è­·ç´°èƒå…å—æå‚·ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–çš„ç‰¹æ€§ã€‚é€™äº›ç‰¹æ€§ä½¿å¾—è˜¿è””ç¡«ç´ æˆç‚ºä¸€å€‹é‡è¦çš„ç ”ç©¶ä¸»é¡Œï¼Œå°¤å…¶æ˜¯åœ¨å°‹æ‰¾æœ‰æ•ˆçš„ç–¾ç—…é é˜²æ–¹æ³•æ–¹é¢ï¼Œå¯èƒ½ç‚ºæˆ‘å€‘æä¾›æ–°çš„æ€è·¯å’Œæ–¹å‘ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¸»è¦ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æŠ—æ°§åŒ–å’Œç™Œç—‡é é˜²æ–¹é¢çš„æ½›åŠ›ã€‚å„˜ç®¡éå»çš„ç ”ç©¶å·²ç¶“æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä½†å°å…¶åœ¨ç´°èƒä»£è¬å±¤é¢çš„å…¨é¢å½±éŸ¿ä»ç„¶ä¸å¤ æ¸…æ¥šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€ç©ºç™½ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠåˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§äº’å‹•æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•ä½¿ç ”ç©¶è€…èƒ½å¤ è©³ç´°äº†è§£è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å…·é«”å½±éŸ¿ï¼Œä¸¦æ¢ç´¢å…¶åœ¨ä¸åŒä»£è¬é€”å¾‘ä¸­çš„ä½œç”¨ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘å’Œè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å…¶æå‡GSHæ°´å¹³çš„èƒ½åŠ›ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†å…¶æŠ—æ°§åŒ–ç‰¹æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å—ï¼Ÿé€™å€‹å°å°çš„åŒ–åˆç‰©æœ€è¿‘å¼•èµ·äº†ç§‘å­¸å®¶çš„æ³¨æ„ï¼Œå› ç‚ºå®ƒå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ä¸å°‘å¥½è™•ï¼\n\næœ€è¿‘ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘ç´°èƒçš„ä»£è¬éç¨‹ã€‚ç ”ç©¶è€…ç”¨äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä¾†é€²è¡Œå¯¦é©—ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®é«˜ç§‘æŠ€çš„æ–¹æ³•ä¾†åˆ†æç´°èƒå…§çš„è®ŠåŒ–ï¼Œçµæœç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—å½±éŸ¿å¤šå€‹é‡è¦çš„ä»£è¬é€”å¾‘ã€‚\n\né€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æå‡æˆ‘å€‘é«”å…§çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œé‚„èƒ½å½±éŸ¿ç³–è§£ä½œç”¨å’Œæ°¨åŸºé…¸çš„ä»£è¬ï¼Œç”šè‡³æé«˜äº†è°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰çš„æ°´å¹³ï¼Œé€™æ˜¯ä¸€ç¨®å°æŠ—æ°§åŒ–çš„é—œéµç‰©è³ªã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n- è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é é˜²ç™Œç—‡å’Œä¿è­·ç´°èƒã€‚\n- é€™é …ç ”ç©¶æ­ç¤ºäº†å®ƒåœ¨ç´°èƒä»£è¬ä¸­çš„å¤šé‡å½±éŸ¿ã€‚\n- æå‡GSHæ°´å¹³ï¼Œé€²ä¸€æ­¥æ”¯æŒå…¶æŠ—æ°§åŒ–ç‰¹æ€§ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶çµæœå§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of the study on sulforaphane. The image should include symbols representing broccoli or sulforaphane, simplified illustrations of human cells, and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' that highlights protective effects and metabolic changes. Use a light background with soft colors and a clear, educational style.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‚ç™Œ Hepatocellular Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41543290/"
  },
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤çš„æŠ‘åˆ¶ç‰¹æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”é±—ç‹€ç´°èƒç™Œçš„ä¸€ç¨®æ½›åœ¨é¸æ“‡ã€‚éš¨è‘—å°é€™é¡ç™Œç—‡çš„æ²»ç™‚éœ€æ±‚æ—¥ç›Šå¢åŠ ï¼Œå°‹æ‰¾å®‰å…¨æœ‰æ•ˆçš„å¤©ç„¶ç™‚æ³•é¡¯å¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„åˆæ­¥è­‰æ“šï¼Œå¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨é‹ªå¹³é“è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£SFN-Cysæ˜¯å¦èƒ½å¤ æŠ‘åˆ¶OSCCçš„é€²å±•ï¼Œä¸¦æ¢ç´¢å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç”±æ–¼ç›®å‰å°SFN-Cysåœ¨å£è…”ç™Œä¸­çš„æ½›åœ¨ä½œç”¨äº†è§£ä¸å¤šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›åŸºç¤ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†OSCCç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°é€™äº›ç´°èƒé€²è¡Œäº†SFN-Cysè™•ç†ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿç´°èƒçš„æ¯’æ€§åæ‡‰ã€ç´°èƒé€±æœŸçš„è®ŠåŒ–ä»¥åŠå‡‹äº¡äº‹ä»¶çš„ä¿ƒé€²ã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†SFN-Cyså¦‚ä½•å½±éŸ¿èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦æª¢æ¸¬äº†ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ï¼ˆå¦‚JNKé€šè·¯ï¼‰åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°OSCCç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»ç¤™ç´°èƒé€±æœŸçš„é€²å±•ï¼Œä¿ƒé€²å‡‹äº¡åæ‡‰ã€‚å…·é«”ä¾†èªªï¼ŒSFN-Cysé™ä½äº†å‡‹äº¡æŠ‘åˆ¶å› å­çš„è¡¨é”ï¼Œä¸¦æ¿€æ´»äº†caspaseç´šè¯åæ‡‰ã€‚æ­¤å¤–ï¼ŒSFN-Cysè™•ç†çš„OSCCç´°èƒåœ¨ä½¿ç”¨ç‰¹å®šçš„JNKæŠ‘åˆ¶åŠ‘é è™•ç†å¾Œï¼Œcaspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜JNKé€šè·¯èˆ‡SFN-Cysåœ¨OSCCç´°èƒä¸­çš„ä½œç”¨æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºå¤©ç„¶åŒ–åˆç‰©åœ¨å£è…”æƒ¡æ€§è…«ç˜¤ç®¡ç†ä¸­çš„æ‡‰ç”¨æä¾›äº†å¯èƒ½çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤çš„æŠ‘åˆ¶ç‰¹æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”é±—ç‹€ç´°èƒç™Œçš„ä¸€ç¨®æ½›åœ¨é¸æ“‡ã€‚éš¨è‘—å°é€™é¡ç™Œç—‡çš„æ²»ç™‚éœ€æ±‚æ—¥ç›Šå¢åŠ ï¼Œå°‹æ‰¾å®‰å…¨æœ‰æ•ˆçš„å¤©ç„¶ç™‚æ³•é¡¯å¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„åˆæ­¥è­‰æ“šï¼Œå¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨é‹ªå¹³é“è·¯ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£SFN-Cysæ˜¯å¦èƒ½å¤ æŠ‘åˆ¶OSCCçš„é€²å±•ï¼Œä¸¦æ¢ç´¢å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç”±æ–¼ç›®å‰å°SFN-Cysåœ¨å£è…”ç™Œä¸­çš„æ½›åœ¨ä½œç”¨äº†è§£ä¸å¤šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›åŸºç¤ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†OSCCç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°é€™äº›ç´°èƒé€²è¡Œäº†SFN-Cysè™•ç†ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿç´°èƒçš„æ¯’æ€§åæ‡‰ã€ç´°èƒé€±æœŸçš„è®ŠåŒ–ä»¥åŠå‡‹äº¡äº‹ä»¶çš„ä¿ƒé€²ã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†SFN-Cyså¦‚ä½•å½±éŸ¿èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦æª¢æ¸¬äº†ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ï¼ˆå¦‚JNKé€šè·¯ï¼‰åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°OSCCç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»ç¤™ç´°èƒé€±æœŸçš„é€²å±•ï¼Œä¿ƒé€²å‡‹äº¡åæ‡‰ã€‚å…·é«”ä¾†èªªï¼ŒSFN-Cysé™ä½äº†å‡‹äº¡æŠ‘åˆ¶å› å­çš„è¡¨é”ï¼Œä¸¦æ¿€æ´»äº†caspaseç´šè¯åæ‡‰ã€‚æ­¤å¤–ï¼ŒSFN-Cysè™•ç†çš„OSCCç´°èƒåœ¨ä½¿ç”¨ç‰¹å®šçš„JNKæŠ‘åˆ¶åŠ‘é è™•ç†å¾Œï¼Œcaspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜JNKé€šè·¯èˆ‡SFN-Cysåœ¨OSCCç´°èƒä¸­çš„ä½œç”¨æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºå¤©ç„¶åŒ–åˆç‰©åœ¨å£è…”æƒ¡æ€§è…«ç˜¤ç®¡ç†ä¸­çš„æ‡‰ç”¨æä¾›äº†å¯èƒ½çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå¯èƒ½å°å£è…”ç™Œæœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰ï¼Œç§‘å­¸å®¶å€‘æƒ³çŸ¥é“å®ƒæ˜¯å¦èƒ½å¤ æŠ‘åˆ¶å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„é€²å±•ï¼Œä¸¦æ¢ç´¢å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†OSCCç´°èƒï¼Œä¸¦å°é€™äº›ç´°èƒé€²è¡Œäº†SFN-Cysçš„è™•ç†ã€‚ä»–å€‘è§€å¯Ÿäº†ç´°èƒçš„åæ‡‰ï¼Œå°¤å…¶æ˜¯ç´°èƒçš„æ­»äº¡å’Œé€±æœŸè®ŠåŒ–ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦é˜»ç¤™å®ƒå€‘çš„å¢é•·ã€‚å…·é«”ä¾†èªªï¼Œå®ƒé™ä½äº†æŸäº›æŠ‘åˆ¶ç´°èƒæ­»äº¡çš„å› å­ï¼Œä¸¦ä¿ƒé€²äº†ç´°èƒè‡ªæˆ‘æ¯€æ»…çš„éç¨‹ã€‚  \n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´äº†è§£è˜¿è””ç¡«ç´ å¯èƒ½åœ¨å£è…”ç™Œæ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œæœªä¾†æˆ–è¨±èƒ½æˆç‚ºä¸€ç¨®å¤©ç„¶çš„è¼”åŠ©ç™‚æ³•ï¼  \n\nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æŠ‘åˆ¶å£è…”ç™Œç´°èƒçš„å¢é•·ã€‚  \n2. å®ƒèƒ½ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ï¼Œæ”¹è®Šç´°èƒçš„ç”Ÿé•·é€±æœŸã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on sulforaphane-cysteine (SFN-Cys) and oral squamous cell carcinoma (OSCC). Include symbols of broccoli or sulforaphane, simplified illustrations of experimental subjects like cells or people, and arrows or flow lines to indicate the steps of the experiment. Add a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æé«˜é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—èŒï¼Œé€™å¯èƒ½å°å¢å¼·å…ç–«ç³»çµ±å’Œé é˜²æŸäº›ç–¾ç—…æœ‰æ­£é¢å½±éŸ¿ã€‚é€éé©ç•¶çš„è™•ç†æ–¹æ³•ï¼Œåƒæ˜¯æ–½åŠ è”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œå¯ä»¥é€²ä¸€æ­¥æå‡é’èŠ±æ¤°èœçš„å¥åº·æˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿçš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–çƒ¯çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€šéç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æé«˜é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦ä¸”è©•ä¼°é€™äº›è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªæœ‰ä½•å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦æ–½åŠ äº†è”—ç³–å£“åŠ›è™•ç†ï¼Œè§€å¯Ÿå…¶å°è‘¡è„ç³–çƒ¯åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œä»¥è©•ä¼°èŠ½ç²‰çš„å“è³ªã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…èƒ½å¤ åˆ†æä¸åŒè™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ï¼Œä¸¦æ¸¬è©¦å…¶æŠ—èŒæ´»æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ–½åŠ è”—ç³–è™•ç†å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–çƒ¯å«é‡æå‡äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æé«˜é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºæœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—èŒï¼Œé€™å¯èƒ½å°å¢å¼·å…ç–«ç³»çµ±å’Œé é˜²æŸäº›ç–¾ç—…æœ‰æ­£é¢å½±éŸ¿ã€‚é€éé©ç•¶çš„è™•ç†æ–¹æ³•ï¼Œåƒæ˜¯æ–½åŠ è”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œå¯ä»¥é€²ä¸€æ­¥æå‡é’èŠ±æ¤°èœçš„å¥åº·æˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿçš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–çƒ¯çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€šéç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æé«˜é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦ä¸”è©•ä¼°é€™äº›è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªæœ‰ä½•å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦æ–½åŠ äº†è”—ç³–å£“åŠ›è™•ç†ï¼Œè§€å¯Ÿå…¶å°è‘¡è„ç³–çƒ¯åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†çœŸç©ºå†·å‡ä¹¾ç‡¥ï¼Œä»¥è©•ä¼°èŠ½ç²‰çš„å“è³ªã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…èƒ½å¤ åˆ†æä¸åŒè™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ï¼Œä¸¦æ¸¬è©¦å…¶æŠ—èŒæ´»æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ–½åŠ è”—ç³–è™•ç†å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–çƒ¯å«é‡æå‡äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”å…·æœ‰å„ªè‰¯çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰å€‹è¶…ç´šæˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿé€™å€‹æˆåˆ†ä¸åƒ…èƒ½å¹«åŠ©æˆ‘å€‘æŠ—æ°§åŒ–ï¼Œé‚„å¯èƒ½å°å¢å¼·å…ç–«ç³»çµ±æœ‰å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†å¦‚ä½•æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†è”—ç³–å£“åŠ›è™•ç†å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥é€™å…©ç¨®æ–¹æ³•ï¼Œä¾†çœ‹çœ‹é€™äº›æŠ€è¡“èƒ½å¦è®“é’èŠ±æ¤°èœèŠ½è®Šå¾—æ›´ç‡Ÿé¤Šã€æ›´å¥½åƒã€‚ \n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘ç™¼ç¾æ–½åŠ è”—ç³–å£“åŠ›å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–çƒ¯å«é‡ç«Ÿç„¶æå‡äº†316.30%ï¼è€Œä¸”ï¼Œç¶“éçœŸç©ºå†·å‡ä¹¾ç‡¥è™•ç†çš„é’èŠ±æ¤°èœèŠ½ç²‰ï¼Œå°æ–¼è˜¿è””ç¡«ç´ å’Œå…¶ä»–å¥åº·æˆåˆ†çš„ä¿ç•™è¡¨ç¾ä¹Ÿéå¸¸å„ªç§€ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œé€™äº›è™•ç†æ–¹æ³•å¯èƒ½ç‚ºæˆ‘å€‘çš„é£²é£Ÿå¸¶ä¾†æ›´å¤šå¥åº·çš„é¸æ“‡ã€‚\n\nâœ¨ ä¸»è¦é‡é»ï¼š\n1. è”—ç³–å£“åŠ›è™•ç†èƒ½å¤§å¹…æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“æœ‰åŠ©æ–¼ä¿æŒé’èŠ±æ¤°èœèŠ½ç²‰çš„å¥åº·æˆåˆ†ã€‚\n3. é€™äº›æ–¹æ³•å¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›æ–°æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on broccoli sprouts. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli and sulforaphane, simplified icons of experimental subjects like humans or cells, arrows or flow lines to indicate the steps of the experiment, and a section labeled 'Main Results' highlighting key findings such as nutrient increases and protective effects.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…å¯èƒ½å…·æœ‰æ½›åœ¨åƒ¹å€¼ã€‚é€™äº›æˆåˆ†çš„æŠ—ç™¼ç‚ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ…¢æ€§ç–¾ç—…çš„é¢¨éšªï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¾ä»£ç¤¾æœƒä¸­ï¼Œç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»å£“åŠ›æ—¥ç›Šå¢åŠ çš„æƒ…æ³ä¸‹ï¼Œé€™æ¨£çš„ç ”ç©¶çµæœå°¤ç‚ºé‡è¦ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å‘¼å¸ç³»çµ±çš„å¥åº·ï¼Œä¸¦æ¸›å°‘ç›¸é—œç–¾ç—…çš„ç™¼ç”Ÿã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚å¯¦é©—ä¸­ä½¿ç”¨çš„GO-PEGå¥ˆç±³ç²’å­æ˜¯å¾çŸ³å¢¨è£½æˆçš„ï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°é€™äº›ç‰©è³ªå°BEAS-2Bç´°èƒçš„å½±éŸ¿ï¼Œä¸¦æ¸¬é‡ç´°èƒå­˜æ´»ç‡å’Œç”ŸåŒ–æŒ‡æ¨™ï¼Œä»¥äº†è§£å®ƒå€‘çš„ç´°èƒæ¯’æ€§å’Œç”Ÿç‰©æ´»æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ²»ç™‚æ‡‰ç”¨åƒ¹å€¼ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºäº†é€™äº›ç‰©è³ªçš„æ­£é¢æ•ˆæ‡‰ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶åœ¨è‡¨åºŠä¸Šçš„å¯¦éš›æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…å¯èƒ½å…·æœ‰æ½›åœ¨åƒ¹å€¼ã€‚é€™äº›æˆåˆ†çš„æŠ—ç™¼ç‚ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ…¢æ€§ç–¾ç—…çš„é¢¨éšªï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¾ä»£ç¤¾æœƒä¸­ï¼Œç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»å£“åŠ›æ—¥ç›Šå¢åŠ çš„æƒ…æ³ä¸‹ï¼Œé€™æ¨£çš„ç ”ç©¶çµæœå°¤ç‚ºé‡è¦ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å‘¼å¸ç³»çµ±çš„å¥åº·ï¼Œä¸¦æ¸›å°‘ç›¸é—œç–¾ç—…çš„ç™¼ç”Ÿã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚å¯¦é©—ä¸­ä½¿ç”¨çš„GO-PEGå¥ˆç±³ç²’å­æ˜¯å¾çŸ³å¢¨è£½æˆçš„ï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°é€™äº›ç‰©è³ªå°BEAS-2Bç´°èƒçš„å½±éŸ¿ï¼Œä¸¦æ¸¬é‡ç´°èƒå­˜æ´»ç‡å’Œç”ŸåŒ–æŒ‡æ¨™ï¼Œä»¥äº†è§£å®ƒå€‘çš„ç´°èƒæ¯’æ€§å’Œç”Ÿç‰©æ´»æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ²»ç™‚æ‡‰ç”¨åƒ¹å€¼ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºäº†é€™äº›ç‰©è³ªçš„æ­£é¢æ•ˆæ‡‰ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶åœ¨è‡¨åºŠä¸Šçš„å¯¦éš›æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„é£Ÿæï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç¥å¥‡çš„å½±éŸ¿ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°å‘¼å¸é“å¥åº·å¯èƒ½éå¸¸æœ‰å¹«åŠ©å“¦ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ¢è¨ä¸€äº›å¤©ç„¶æˆåˆ†ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé»‘è˜¿è””çš„å¤©ç„¶ç‰©è³ªï¼‰å’ŒPEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼Œé€™æ˜¯ä¸€ç¨®å¥ˆç±³ææ–™ï¼‰ï¼Œå°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ç”¨å¯¦é©—å®¤æ–¹æ³•å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦æ¸¬è©¦é€™äº›æˆåˆ†å°ç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ä¸€ç¨®åç‚ºIL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦æå‡æˆ‘å€‘é«”å…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œé€™äº›éƒ½æ˜¯æœ‰ç›Šæ–¼å¥åº·çš„å¥½ç¾è±¡ï¼é›–ç„¶é€™äº›çµæœå¾ˆä»¤äººæŒ¯å¥®ï¼Œä½†æˆ‘å€‘é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›æˆåˆ†åœ¨è‡¨åºŠä¸Šçš„å¯¦éš›æ•ˆæœã€‚\n\nğŸ”‘ é€™è£¡æœ‰å¹¾å€‹é‡è¦çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼å‘¼å¸é“å¥åº·ã€‚\n2. é€™äº›æˆåˆ†èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºèªå…¶å¯¦éš›æ•ˆæœã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on the effects of sulforaphane and black radish juice on human bronchial epithelial cells. Include simplified illustrations of black radish and sulforaphane, representations of human cells, and arrows or flow lines to indicate experimental steps. Highlight a section for 'Main Results' showing protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41487499",
    "title_en": "The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "The inflammatory bowel disease (IBD) ulcerative colitis (UC) is characterized by continuous inflammation of the colon with erosion and ulcers. Diagnosis typically occurs in patients between their late teens and mid-30s with no cure. Available therapeutics are efficient at controlling symptoms however, they have many serious adverse effects. Thus, additional therapies with limited adverse effects are needed to complement these drugs. In this study, we evaluated the anti-inflammatory potential of carnosic acid (CA), the most abundant diterpene in rosemary (<i>Salvia rosmarinus</i>) and sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. We used colonic epithelial organoids (colonoids) derived from non-IBD and UC patients as a physiologically relevant testing platform for both phytochemicals. These patient-derived colonoids are a representative model that recapitulates the parent epithelial tissue including its cellular composition and 3D structure. Moreover, we cultured the colonoids at 2% O<sub>2</sub> to better approximate the low oxygen level (physioxia) observed in the colon crypts. To assess the effects of CA and SFN in the nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) pathways, we studied modulation of inflammatory cytokines through a 40-plex chemokine assay and ELISA, as well as gene and protein expression of target genes with qPCR and western blot, respectively. Through these techniques, we observed that CA and SFN decreased inflammatory markers and promoted NRF2 activity in patient-derived colonoids. Additionally, SFN and CA modulated the expression and secretion of the NF-ÎºB promoted antibacterial peptide neutrophil gelatinase-associated lipocalin which is highly expressed in the inflamed colonic epithelium and has been suggested as a biomarker for active UC. Together, the results validated the use of colonoids as a pharmacological testing platform for phytochemicals, and that CA and SFN promote NRF2 activation and decrease inflammation in a human physiologically relevant UC model.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚é€™ç¨®ç–¾ç—…é€šå¸¸åœ¨é’å°‘å¹´æ™šæœŸåˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ï¼Œä¸”ç›®å‰å°šç„¡æ²»ç™’æ–¹æ³•ã€‚é›–ç„¶ç¾æœ‰çš„æ²»ç™‚è—¥ç‰©èƒ½æœ‰æ•ˆæ§åˆ¶ç—‡ç‹€ï¼Œä½†å»ä¼´éš¨è‘—è¨±å¤šåš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾å…·æœ‰è¼ƒå°‘å‰¯ä½œç”¨çš„è¼”åŠ©ç™‚æ³•é¡¯å¾—ååˆ†é‡è¦ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼šè¿·è¿­é¦™ä¸­çš„ä¸»è¦äºŒèœé…¸â€”â€”è‚‰æ¡‚é…¸ï¼ˆCAï¼‰ï¼Œä»¥åŠåœ¨åå­—èŠ±ç§‘è”¬èœä¸­ç™¼ç¾çš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©åœ¨æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å¦‚ä½•å½±éŸ¿èˆ‡ç‚ç—‡ç›¸é—œçš„ç´°èƒä¿¡è™Ÿé€šè·¯ï¼Œå¾è€Œç‚ºæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®èƒ½å¤ æ¨¡æ“¬çœŸå¯¦è…¸é“çµ„ç¹”çš„æ¨¡å‹ã€‚ç ”ç©¶è€…åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´å¥½åœ°æ¨¡æ“¬çµè…¸å…§çš„ç”Ÿç†ç‹€æ…‹ã€‚æ¥è‘—ï¼Œä»–å€‘é€šéå¤šç¨®æŠ€è¡“ä¾†è©•ä¼°CAå’ŒSFNå°æ–¼ç‚ç—‡ç´°èƒå› å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬40é‡åŒ–å­¸å› å­æª¢æ¸¬ã€ELISAã€qPCRå’Œè¥¿æ–¹å°è·¡æ³•ç­‰ï¼Œä¾†åˆ†æé€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™åœ¨æ‚£è€…è¡ç”Ÿçš„çµè…¸é¡å™¨å®˜ä¸­å¾—åˆ°äº†é©—è­‰ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½ä¸­æ€§ç²’ç´°èƒæ˜è† é…¶ç›¸é—œè„‚è›‹ç™½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®è›‹ç™½åœ¨ç™¼ç‚çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡è¼ƒé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„æ´»èºç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœæ”¯æŒäº†ä½¿ç”¨çµè…¸é¡å™¨å®˜ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„æœ‰æ•ˆæ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚é€™ç¨®ç–¾ç—…é€šå¸¸åœ¨é’å°‘å¹´æ™šæœŸåˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ï¼Œä¸”ç›®å‰å°šç„¡æ²»ç™’æ–¹æ³•ã€‚é›–ç„¶ç¾æœ‰çš„æ²»ç™‚è—¥ç‰©èƒ½æœ‰æ•ˆæ§åˆ¶ç—‡ç‹€ï¼Œä½†å»ä¼´éš¨è‘—è¨±å¤šåš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾å…·æœ‰è¼ƒå°‘å‰¯ä½œç”¨çš„è¼”åŠ©ç™‚æ³•é¡¯å¾—ååˆ†é‡è¦ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼šè¿·è¿­é¦™ä¸­çš„ä¸»è¦äºŒèœé…¸â€”â€”è‚‰æ¡‚é…¸ï¼ˆCAï¼‰ï¼Œä»¥åŠåœ¨åå­—èŠ±ç§‘è”¬èœä¸­ç™¼ç¾çš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©åœ¨æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å¦‚ä½•å½±éŸ¿èˆ‡ç‚ç—‡ç›¸é—œçš„ç´°èƒä¿¡è™Ÿé€šè·¯ï¼Œå¾è€Œç‚ºæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®èƒ½å¤ æ¨¡æ“¬çœŸå¯¦è…¸é“çµ„ç¹”çš„æ¨¡å‹ã€‚ç ”ç©¶è€…åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´å¥½åœ°æ¨¡æ“¬çµè…¸å…§çš„ç”Ÿç†ç‹€æ…‹ã€‚æ¥è‘—ï¼Œä»–å€‘é€šéå¤šç¨®æŠ€è¡“ä¾†è©•ä¼°CAå’ŒSFNå°æ–¼ç‚ç—‡ç´°èƒå› å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬40é‡åŒ–å­¸å› å­æª¢æ¸¬ã€ELISAã€qPCRå’Œè¥¿æ–¹å°è·¡æ³•ç­‰ï¼Œä¾†åˆ†æé€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™åœ¨æ‚£è€…è¡ç”Ÿçš„çµè…¸é¡å™¨å®˜ä¸­å¾—åˆ°äº†é©—è­‰ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½ä¸­æ€§ç²’ç´°èƒæ˜è† é…¶ç›¸é—œè„‚è›‹ç™½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®è›‹ç™½åœ¨ç™¼ç‚çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡è¼ƒé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„æ´»èºç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœæ”¯æŒäº†ä½¿ç”¨çµè…¸é¡å™¨å®˜ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„æœ‰æ•ˆæ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›è”¬èœè£¡çš„æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„ç–¾ç—…ï¼Œé€šå¸¸åœ¨é’å°‘å¹´åˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ã€‚é›–ç„¶ç¾æœ‰çš„è—¥ç‰©èƒ½å¤ æ§åˆ¶ç—‡ç‹€ï¼Œä½†å‰¯ä½œç”¨å»è®“äººæ“”å¿ƒï¼Œå› æ­¤æ‰¾å°‹æ›´å®‰å…¨çš„è¼”åŠ©ç™‚æ³•è®Šå¾—ç›¸ç•¶é‡è¦ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼šè‚‰æ¡‚é…¸ï¼ˆCAï¼Œä¾†è‡ªè¿·è¿­é¦™ï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼‰ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™äº›æˆåˆ†åœ¨æ½°ç˜æ€§çµè…¸ç‚æ¨¡å‹ä¸­çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å¦‚ä½•å½±éŸ¿ç‚ç—‡çš„ç›¸é—œä¿¡è™Ÿã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰èƒ½æ¨¡æ“¬è…¸é“çµ„ç¹”ï¼Œä¸¦åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šï¼Œä»¥æ›´æ¥è¿‘çœŸå¯¦çš„è…¸é“ç‹€æ…‹ã€‚é€éå¤šç¨®æŠ€è¡“ï¼Œç ”ç©¶è€…å€‘è§€å¯Ÿåˆ°è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²ä¸€ç¨®åç‚ºNRF2çš„æ´»æ€§ï¼Œé€™åœ¨æ‚£è€…çš„çµè…¸é¡å™¨å®˜ä¸­å¾—åˆ°äº†é©—è­‰ã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½æ¸›å°‘è…¸é“ä¸­çš„ç‚ç—‡ã€‚\n2. é€™äº›æˆåˆ†ä¿ƒé€²äº†æœ‰åŠ©æ–¼æŠ—ç‚çš„è›‹ç™½è³ªè¡¨é”ã€‚\n3. ä½¿ç”¨çµè…¸é¡å™¨å®˜é€²è¡Œæ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ¸¬è©¦é¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœã€‚\n\né€™äº›çµæœç‚ºæœªä¾†æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›äº†æ–°çš„å¸Œæœ›ï¼",
    "image_prompt": "Create a simplified infographic that explains the experimental methods and main findings of a study on the anti-inflammatory potential of two plant compounds: cinnamic acid (CA) and sulforaphane (SFN). Include visual elements such as icons representing broccoli and sulforaphane, simplified illustrations of experimental subjects (like human cells), arrows or flow lines to depict the experimental process, and a section labeled 'Main Findings' highlighting protective effects and changes observed in inflammation markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41487499/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®æˆåˆ†è½‰åŒ–è€Œä¾†ï¼Œé›–ç„¶å®ƒå…·æœ‰æ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰åŒ–ç‡è¼ƒä½ï¼Œé€™å¯èƒ½å½±éŸ¿å…¶åœ¨é£²é£Ÿä¸­çš„æœ‰æ•ˆæ€§ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…¶åœ¨é é˜²ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œå’ŒæŠ—ç™¼ç‚ç­‰æ–¹é¢çš„æ‡‰ç”¨ã€‚é€™å°æ–¼å¸Œæœ›é€šéé£²é£Ÿæ”¹å–„å¥åº·çš„äººå€‘ä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å‰é«”â€”â€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™ç¨®è½‰åŒ–éç¨‹çš„æ•ˆç‡ä½ä¸‹ï¼Œä¸¦ä¸”ç›®å‰å°æ–¼ä¹³é…¸èŒå¦‚ä½•é€²è¡Œé€™ä¸€è½‰åŒ–çš„æ©Ÿåˆ¶ä»ä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€è½‰åŒ–éç¨‹çš„ç”Ÿç‰©å­¸åŸºç¤ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰åŒ–ç‡çš„æ–¹æ³•ï¼Œä»¥ä¾¿æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„å¥åº·ç›Šè™•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒå°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°å…¶ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€éè½‰éŒ„çµ„åˆ†æï¼Œç ”ç©¶è€…èƒ½å¤ äº†è§£é€™äº›èŒæ ªåœ¨ä»£è¬éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œä¸¦æ¢ç´¢å…¶è½‰åŒ–è·¯å¾‘ï¼Œé€™æœ‰åŠ©æ–¼æ­ç¤ºå¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥ä¿ƒé€²è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ã€‚ç ”ç©¶çµæœé‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„é€²å£åŠå…¶å¾ŒçºŒçš„ç£·é…¸åŒ–éç¨‹ï¼Œæœ€çµ‚å°è‡´è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ä¹³é…¸èŒçš„ä»£è¬æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®æˆåˆ†è½‰åŒ–è€Œä¾†ï¼Œé›–ç„¶å®ƒå…·æœ‰æ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰åŒ–ç‡è¼ƒä½ï¼Œé€™å¯èƒ½å½±éŸ¿å…¶åœ¨é£²é£Ÿä¸­çš„æœ‰æ•ˆæ€§ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…¶åœ¨é é˜²ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œå’ŒæŠ—ç™¼ç‚ç­‰æ–¹é¢çš„æ‡‰ç”¨ã€‚é€™å°æ–¼å¸Œæœ›é€šéé£²é£Ÿæ”¹å–„å¥åº·çš„äººå€‘ä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å‰é«”â€”â€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™ç¨®è½‰åŒ–éç¨‹çš„æ•ˆç‡ä½ä¸‹ï¼Œä¸¦ä¸”ç›®å‰å°æ–¼ä¹³é…¸èŒå¦‚ä½•é€²è¡Œé€™ä¸€è½‰åŒ–çš„æ©Ÿåˆ¶ä»ä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€è½‰åŒ–éç¨‹çš„ç”Ÿç‰©å­¸åŸºç¤ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰åŒ–ç‡çš„æ–¹æ³•ï¼Œä»¥ä¾¿æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„å¥åº·ç›Šè™•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒå°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å°å…¶ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€éè½‰éŒ„çµ„åˆ†æï¼Œç ”ç©¶è€…èƒ½å¤ äº†è§£é€™äº›èŒæ ªåœ¨ä»£è¬éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œä¸¦æ¢ç´¢å…¶è½‰åŒ–è·¯å¾‘ï¼Œé€™æœ‰åŠ©æ–¼æ­ç¤ºå¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥ä¿ƒé€²è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ã€‚ç ”ç©¶çµæœé‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„é€²å£åŠå…¶å¾ŒçºŒçš„ç£·é…¸åŒ–éç¨‹ï¼Œæœ€çµ‚å°è‡´è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ä¹³é…¸èŒçš„ä»£è¬æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¾ˆæœ‰å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œå’ŒæŠ—ç™¼ç‚æ–¹é¢ï¼ä½†æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ä¸é«˜ï¼Œé€™è®“å®ƒåœ¨é£²é£Ÿä¸­çš„æ•ˆæœå—åˆ°å½±éŸ¿ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•æé«˜é€™ç¨®æˆåˆ†çš„è½‰åŒ–ç‡ï¼Œè®“æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨å®ƒçš„å¥åº·ç›Šè™•ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†ä¸€ç¨®å«ä¹³é…¸èŒçš„ç´°èŒï¼ˆå…¶å¯¦å®ƒå€‘å°æˆ‘å€‘çš„è…¸é“å¥åº·å¾ˆé‡è¦ï¼ï¼‰å¦‚ä½•å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªè½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œè§€å¯Ÿä¸åŒçš„åŸ¹é¤Šæ¢ä»¶å°ä¹³é…¸èŒè½‰åŒ–èƒ½åŠ›çš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç•¶æ”¹è®ŠåŸ¹é¤Šæ¢ä»¶æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒæ¸›å°‘ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡æœƒå¢åŠ ï¼Œé€™æ¨£æœ‰åŠ©æ–¼æå‡è˜¿è””ç¡«ç´ çš„ç”Ÿæˆï¼é€™äº›ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘æ›´äº†è§£é€™äº›ç´°èŒçš„é‹ä½œï¼Œä¹Ÿç‚ºæœªä¾†å¥åº·ç”¢å“çš„é–‹ç™¼æä¾›äº†æ–°æ€è·¯ã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ—ç™Œå’ŒæŠ—ç™¼ç‚ã€‚\n2. ä¹³é…¸èŒèƒ½æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚\n3. æ”¹è®ŠåŸ¹é¤Šæ¢ä»¶å¯ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of the study on sulforaphane. Include symbols for broccoli and sulforaphane, simplified representations of the experimental subjects (like people or cells), arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting the increase in sulforaphane production and the metabolic changes in lactobacilli. Use a light background with soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41412441",
    "title_en": "Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: Proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œç ”ç©¶é¡¯ç¤ºå®ƒåœ¨å°æŠ—ç™¼ç‚æ€§ç–¾ç—…æ–¹é¢æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·å’Œè‚è‡ŸåŠŸèƒ½æ–¹é¢ã€‚é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é é˜²èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„è‚è‡Ÿæå‚·ï¼Œé€™å°æ–¼æå‡æ•´é«”å¥åº·ç‹€æ³æ˜¯ç›¸ç•¶é‡è¦çš„ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¸é“ç™¼ç‚å’Œå…¶ä»–ä½µç™¼ç—‡ï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨å°æ–¼æ”¹å–„é€™é¡ç–¾ç—…çš„æ²»ç™‚éå¸¸é‡è¦ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œè€é¼ è¢«çµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå…¶å°è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ã€‚ç ”ç©¶è€…è©•ä¼°äº†è…¸é“çš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½åƒæ•¸ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ä»¥åŠç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦åˆ†æäº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦å’Œå·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½åƒæ•¸ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼ŒæŠ‘åˆ¶M1å‹ä¸¦ä¿ƒé€²M2å‹çš„è¡¨ç¾ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚æå‚·ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œç ”ç©¶é¡¯ç¤ºå®ƒåœ¨å°æŠ—ç™¼ç‚æ€§ç–¾ç—…æ–¹é¢æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·å’Œè‚è‡ŸåŠŸèƒ½æ–¹é¢ã€‚é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é é˜²èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„è‚è‡Ÿæå‚·ï¼Œé€™å°æ–¼æå‡æ•´é«”å¥åº·ç‹€æ³æ˜¯ç›¸ç•¶é‡è¦çš„ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¸é“ç™¼ç‚å’Œå…¶ä»–ä½µç™¼ç—‡ï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨å°æ–¼æ”¹å–„é€™é¡ç–¾ç—…çš„æ²»ç™‚éå¸¸é‡è¦ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œè€é¼ è¢«çµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå…¶å°è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ã€‚ç ”ç©¶è€…è©•ä¼°äº†è…¸é“çš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½åƒæ•¸ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ä»¥åŠç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦åˆ†æäº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦å’Œå·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½åƒæ•¸ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼ŒæŠ‘åˆ¶M1å‹ä¸¦ä¿ƒé€²M2å‹çš„è¡¨ç¾ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚æå‚·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“å¥åº·å’Œè‚è‡ŸåŠŸèƒ½æ¯æ¯ç›¸é—œï¼Œè€Œä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½æœƒæˆç‚ºæˆ‘å€‘çš„å¥åº·å°å¹«æ‰‹ï¼é€™ç¨®åŒ–åˆç‰©ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œåƒæ˜¯é’èŠ±æ¤°èœå’Œè˜¿è””ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°æŠ—ç™¼ç‚æ€§ç–¾ç—…æœ‰æ½›åœ¨çš„å¥½è™•ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ï¼Œæœƒå¼•èµ·è…¸é“ç™¼ç‚å’Œå…¶ä»–ä½µç™¼ç—‡ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç‰¹æ®Šçš„è€é¼ æ¨¡å‹ï¼Œçµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿè…¸é“å’Œè‚è‡Ÿçš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·è…¸é“çš„å±éšœåŠŸèƒ½ï¼Œå¹«åŠ©æˆ‘å€‘çš„èº«é«”æŠµæŠ—ç™¼ç‚ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œæœ‰åŠ©æ–¼è…¸é“å¥åº·ã€‚  \n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„è‚æå‚·ã€‚  \n3. å¢å¼·è…¸é“å±éšœåŠŸèƒ½ï¼Œé™ä½ç™¼ç‚åæ‡‰ï¼",
    "image_prompt": "Create a flat design infographic with a light background illustrating the research on the protective effects of sulforaphane on ulcerative colitis and liver damage. Include simplified icons of broccoli and sulforaphane, a simplified representation of mice as experimental subjects, arrows or flow lines showing the experimental process, and a section highlighting the main results such as protective effects and improvements in liver function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœå’Œå‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œå¯èƒ½æœƒæä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœå…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“ï¼Œå¦‚æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„åˆæˆæ··åˆç‰©ï¼Œä¾†æé«˜æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶çš„ç›®çš„æ˜¯è¨­è¨ˆå’Œåˆæˆæ–°çš„è—¥ç‰©è¡ç”Ÿç‰©ï¼Œä»¥æœŸæ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦è©•ä¼°é€™äº›æ–°åŒ–åˆç‰©çš„æŠ—ç™Œæ´»æ€§ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›åŒ–åˆç‰©åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­é€²è¡Œäº†é«”å¤–æ¸¬è©¦ï¼Œç‰¹åˆ¥é—œæ³¨å®ƒå€‘å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–å’Œå…¶ä»–æƒ¡æ€§è¡Œç‚ºï¼Œä¸¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚æ©Ÿåˆ¶ç ”ç©¶é¡¯ç¤ºï¼Œ17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€”å¾‘ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ½›åœ¨å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœå’Œå‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°çš„å¤©ç„¶ç”¢å“æˆ–å…¶åˆæˆè¡ç”Ÿç‰©ï¼Œå¯èƒ½æœƒæä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœå…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢å“ï¼Œå¦‚æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘çš„åˆæˆæ··åˆç‰©ï¼Œä¾†æé«˜æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶çš„ç›®çš„æ˜¯è¨­è¨ˆå’Œåˆæˆæ–°çš„è—¥ç‰©è¡ç”Ÿç‰©ï¼Œä»¥æœŸæ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦è©•ä¼°é€™äº›æ–°åŒ–åˆç‰©çš„æŠ—ç™Œæ´»æ€§ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›åŒ–åˆç‰©åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­é€²è¡Œäº†é«”å¤–æ¸¬è©¦ï¼Œç‰¹åˆ¥é—œæ³¨å®ƒå€‘å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–å’Œå…¶ä»–æƒ¡æ€§è¡Œç‚ºï¼Œä¸¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚æ©Ÿåˆ¶ç ”ç©¶é¡¯ç¤ºï¼Œ17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€”å¾‘ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ½›åœ¨å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£çºçš„ç™Œç—‡ï¼Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„å‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…å¾ˆå›°æ“¾ã€‚ç ”ç©¶è€…å€‘æ­£åœ¨å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œä¸¦ä¸”ç™¼ç¾äº†æœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ é€™å…©ç¨®å¤©ç„¶æˆåˆ†çš„æ½›åŠ›ã€‚  \n  \nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤ä¸­æ¸¬è©¦å®ƒå€‘å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘è§€å¯Ÿäº†é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„å¢æ®–å’Œå…¶ä»–æƒ¡æ€§è¡Œç‚ºï¼Œç”šè‡³åœ¨å°é¼ æ¨¡å‹ä¸­æ¸¬è©¦äº†å®ƒå€‘å°è…«ç˜¤ç”Ÿé•·çš„å½±éŸ¿ã€‚  \n  \næœ€ä»¤äººèˆˆå¥®çš„æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œé‚„èƒ½èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸”åœ¨å°é¼ å¯¦é©—ä¸­æœªé¡¯ç¤ºæ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›çµæœè®“äººæœŸå¾…17aæœ‰å¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ–°é¸æ“‡ï¼  \n  \nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. å°‹æ‰¾æ–°å¤©ç„¶æŠ—ç™Œè—¥ç‰©éå¸¸é‡è¦ã€‚  \n2. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ•ˆæœã€‚  \n3. é€™äº›ç ”ç©¶çµæœç‚ºæœªä¾†çš„è‡¨åºŠç ”ç©¶é‹ªè·¯ï¼Œå€¼å¾—é—œæ³¨ï¼",
    "image_prompt": "Create an infographic that visually explains the experimental methods and main findings of a study on natural compounds for treating triple-negative breast cancer. Use a flat design style with a white or light-colored background and soft colors. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to represent the experimental steps. Dedicate a section to highlight the 'Main Findings', showcasing protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå¯ä»¥æ¿€æ´»Nrf2ï¼Œä¸¦ä¸”é€šå¸¸èˆ‡æ¸›å°‘ç‚ç—‡åæ‡‰æœ‰é—œï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæ›´ç‚ºè¤‡é›œã€‚ç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¾Œï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒåŒæ™‚æŠ‘åˆ¶æŸäº›å…ç–«ç´°èƒçš„æµ¸æ½¤ï¼Œä½†å»ä¿ƒé€²äº†å…¶ä»–å…ç–«ç´°èƒçš„æ‹›å‹Ÿï¼Œé€™é¡¯ç¤ºå‡ºåœ¨ç’°å¢ƒæ±¡æŸ“ç‰©å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœä¸¦ä¸æ˜¯å–®ä¸€çš„ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ä¾†æ·±å…¥äº†è§£Nrf2åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ï¼Œå› ç‚ºå…ˆå‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨å°é¼ ä¸­æ„å¤–ä¿ƒé€²äº†ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ï¼Œé€™èˆ‡å®ƒé€šå¸¸è¢«èªç‚ºçš„æŠ‘åˆ¶ç‚ç—‡çš„è§’è‰²ç›¸çŸ›ç›¾ï¼Œå› æ­¤éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ è¢«éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸äº†ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦éš¨å¾Œæ¥å—äº†ç‚ºæœŸ14å¤©çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶è€…æ”¶é›†äº†æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä»¥é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æï¼Œé‚„é‡åŒ–äº†ç´°èƒå› å­æˆ–è¶¨åŒ–å› å­çš„mRNAè¡¨é”ä»¥åŠNrf2è›‹ç™½åœ¨ç´°èƒæ ¸æå–ç‰©ä¸­çš„å«é‡ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ï¼Œä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½äº†IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡è™•ç†ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤å’Œç‚ç—‡åæ‡‰ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ åœ¨å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡Nrf2çš„æ´»åŒ–æœ‰é—œã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå¯ä»¥æ¿€æ´»Nrf2ï¼Œä¸¦ä¸”é€šå¸¸èˆ‡æ¸›å°‘ç‚ç—‡åæ‡‰æœ‰é—œï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæ›´ç‚ºè¤‡é›œã€‚ç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¾Œï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœƒåŒæ™‚æŠ‘åˆ¶æŸäº›å…ç–«ç´°èƒçš„æµ¸æ½¤ï¼Œä½†å»ä¿ƒé€²äº†å…¶ä»–å…ç–«ç´°èƒçš„æ‹›å‹Ÿï¼Œé€™é¡¯ç¤ºå‡ºåœ¨ç’°å¢ƒæ±¡æŸ“ç‰©å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœä¸¦ä¸æ˜¯å–®ä¸€çš„ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ä¾†æ·±å…¥äº†è§£Nrf2åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ï¼Œå› ç‚ºå…ˆå‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨å°é¼ ä¸­æ„å¤–ä¿ƒé€²äº†ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ï¼Œé€™èˆ‡å®ƒé€šå¸¸è¢«èªç‚ºçš„æŠ‘åˆ¶ç‚ç—‡çš„è§’è‰²ç›¸çŸ›ç›¾ï¼Œå› æ­¤éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ è¢«éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸äº†ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦éš¨å¾Œæ¥å—äº†ç‚ºæœŸ14å¤©çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶è€…æ”¶é›†äº†æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä»¥é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æï¼Œé‚„é‡åŒ–äº†ç´°èƒå› å­æˆ–è¶¨åŒ–å› å­çš„mRNAè¡¨é”ä»¥åŠNrf2è›‹ç™½åœ¨ç´°èƒæ ¸æå–ç‰©ä¸­çš„å«é‡ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ï¼Œä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½äº†IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡è™•ç†ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤å’Œç‚ç—‡åæ‡‰ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ åœ¨å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡Nrf2çš„æ´»åŒ–æœ‰é—œã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€ç¨®ç¥å¥‡çš„ç‰©è³ªå«åšè˜¿è””ç¡«ç´ ï¼Œå®ƒå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰è‘—æ„æƒ³ä¸åˆ°çš„å½±éŸ¿ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ å°è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯ç•¶æˆ‘å€‘æ¥è§¸åˆ°ä¸€äº›ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œæ¯”å¦‚å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰æ™‚ã€‚ç ”ç©¶è€…å€‘ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œè®“å®ƒå€‘å¸å…¥ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ å¯ä»¥æ¸›å°‘è‚ºéƒ¨çš„é‡é‡å¢åŠ å’Œä¸€äº›ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒå»å¯èƒ½ä¿ƒé€²å…¶ä»–å…ç–«ç´°èƒçš„æ‹›å‹Ÿï¼Œé€™è®“äººæ„Ÿåˆ°æ„å¤–ã€‚ é€™é …ç ”ç©¶æé†’æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ åœ¨é¢å°ç’°å¢ƒæ±¡æŸ“æ™‚çš„ä½œç”¨æ˜¯è¤‡é›œçš„ï¼Œæœªä¾†çš„å¥åº·å¹²é æªæ–½å¯èƒ½éœ€è¦æ›´å¤šçš„æ€è€ƒã€‚ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š 1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‚ºéƒ¨ç‚ç—‡ï¼Œä½†æ•ˆæœå› æƒ…æ³è€Œç•°ã€‚ 2. ç’°å¢ƒæ±¡æŸ“ç‰©å¯èƒ½æ”¹è®Šè˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚ 3. äº†è§£Nrf2ï¼ˆç´°èƒä¿è­·è›‹ç™½ï¼‰åœ¨é€™éç¨‹ä¸­çš„è§’è‰²ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of a study on the effects of sulforaphane on lung inflammation caused by multi-walled carbon nanotubes. Include simplified icons representing broccoli or sulforaphane, experimental subjects like mice, and arrows or flow lines showing the experimental steps. Add a section labeled 'Main Results' highlighting protective effects and changes observed, with a light background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºéƒ¨ç‚ç—‡ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘æ¤ç‰©çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ ä¿ƒé€²æŸäº›å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°é›£æ²»æ€§ç™Œç—‡çš„æ²»ç™‚ä¸Šã€‚ç„¶è€Œï¼Œé€™é …ç ”ç©¶ä¹Ÿæé†’æˆ‘å€‘ï¼Œä½¿ç”¨ä»»ä½•æŠ—ç™Œè—¥ç‰©æ™‚ï¼Œéƒ½éœ€è¦è€ƒæ…®å…¶å¯èƒ½çš„å‰¯ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å°å¿ƒè‡Ÿçš„å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ä»¥åŠå°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒä¸­ï¼ˆå¦‚å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒï¼‰æ‰€å±•ç¾çš„æ•ˆæœï¼Œä»¥åŠå®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç†è§£ç™Œç—‡æ²»ç™‚ä¸­çš„å‰¯ä½œç”¨éå¸¸é‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰ä¾†é€²è¡Œå…±åŸ¹é¤Šã€‚é€™ç¨®å…±åŸ¹é¤Šæ¨¡å‹ä½¿å¾—ç ”ç©¶è€…èƒ½å¤ åŒæ™‚è§€å¯Ÿè˜¿è””ç¡«ç´ å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°äº†å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆä¿ƒé€²PC-3å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œä½†å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸäº›æƒ…æ³ä¸‹æœ‰åŠ©æ–¼æ¸›å°‘ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶ç™Œç—‡æ²»ç™‚ä¸­çš„å‰¯ä½œç”¨æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘æ¤ç‰©çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ ä¿ƒé€²æŸäº›å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°é›£æ²»æ€§ç™Œç—‡çš„æ²»ç™‚ä¸Šã€‚ç„¶è€Œï¼Œé€™é …ç ”ç©¶ä¹Ÿæé†’æˆ‘å€‘ï¼Œä½¿ç”¨ä»»ä½•æŠ—ç™Œè—¥ç‰©æ™‚ï¼Œéƒ½éœ€è¦è€ƒæ…®å…¶å¯èƒ½çš„å‰¯ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å°å¿ƒè‡Ÿçš„å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•ä¿ƒé€²ç™Œç´°èƒçš„æ­»äº¡ä»¥åŠå°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒä¸­ï¼ˆå¦‚å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒï¼‰æ‰€å±•ç¾çš„æ•ˆæœï¼Œä»¥åŠå®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼ç†è§£ç™Œç—‡æ²»ç™‚ä¸­çš„å‰¯ä½œç”¨éå¸¸é‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰ä¾†é€²è¡Œå…±åŸ¹é¤Šã€‚é€™ç¨®å…±åŸ¹é¤Šæ¨¡å‹ä½¿å¾—ç ”ç©¶è€…èƒ½å¤ åŒæ™‚è§€å¯Ÿè˜¿è””ç¡«ç´ å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°äº†å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆä¿ƒé€²PC-3å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œä½†å°å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸäº›æƒ…æ³ä¸‹æœ‰åŠ©æ–¼æ¸›å°‘ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶ç™Œç—‡æ²»ç™‚ä¸­çš„å‰¯ä½œç”¨æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ è˜¿è””ä¹Ÿèƒ½æŠ—ç™Œï¼Ÿä½ æ²’è½éŒ¯ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªåå­—èŠ±ç§‘æ¤ç‰©çš„è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒæœ‰è‘—é©šäººçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å¹«åŠ©ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠå°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å½±éŸ¿ã€‚ä»–å€‘ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆä¿ƒé€²æŸäº›å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œä¸¦ä¸”å°å¿ƒè‡Ÿç´°èƒçš„æ”¶ç¸®åŠ›æ²’æœ‰æ˜é¡¯å½±éŸ¿ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œç•¶ç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒä¸€èµ·åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‡Ÿç´°èƒçš„è·³å‹•æ¨¡å¼è®Šå¾—æ›´è¦å¾‹ï¼Œé€™æˆ–è¨±èƒ½æ¸›å°‘æŠ—ç™Œè—¥ç‰©å°å¿ƒè‡Ÿçš„å‚·å®³ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½ä¿ƒé€²å‰åˆ—è…ºç™Œç´°èƒæ­»äº¡ã€‚\n2. å°å¿ƒè‡Ÿç´°èƒçš„æ”¶ç¸®åŠ›å½±éŸ¿ä¸å¤§ã€‚\n3. å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§ã€‚\n\né€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šçš„ç ”ç©¶æˆæœï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane. Include simple illustrations of broccoli or sulforaphane, simplified representations of prostate cancer cells and heart cells. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' highlighting the protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§æœ‰åŠ©æ–¼é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç”Ÿï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½å¯ä»¥é–‹ç™¼å‡ºæ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°æ‡‰å°é€™äº›å¥åº·å•é¡Œã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶æ”¹è‰¯å½¢å¼ï¼Œå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ½›åœ¨å·¥å…·ï¼Œé€™å°æ–¼æå‡æˆ‘å€‘çš„å¥åº·ç‹€æ…‹æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©åœ¨èª¿ç¯€äººé¡æ¨¹çªç´°èƒå…ç–«åæ‡‰ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨é€™äº›åŒ–åˆç‰©ä¾†ä¿ƒé€²æ¨¹çªç´°èƒçš„è€å—æ€§ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶é›†ä¸­åœ¨è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çµåˆå¾Œï¼Œå°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒçš„å½±éŸ¿ï¼Œä¸¦æ¢è¨NFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç½®æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–å’Œè˜¿è””ç¡«ç´ -å‘‹å–ƒç³–é€²è¡Œè™•ç†ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›æ¨¹çªç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€å°Tç´°èƒçš„èª¿ç¯€èƒ½åŠ›ä»¥åŠNFATc1çš„ä¿¡è™Ÿå‚³å°ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒå½¢å¼çš„è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä¸¦ç¢ºèªNFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„é‡è¦æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å¤§äº†èª¿ç¯€æ€§Tç´°èƒçš„æ•¸é‡ï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œåªæœ‰è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èƒ½ä¿ƒé€²NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œé€™ä¸€éç¨‹åœ¨ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1å¾Œè¢«é˜»æ­¢ï¼Œé¡¯ç¤ºNFATc1åœ¨è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èª˜å°å…ç–«è€å—ä¸­çš„é—œéµä½œç”¨ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å…ç–«è€å—æ€§æ–¹é¢ã€‚å…ç–«è€å—æ€§æœ‰åŠ©æ–¼é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç™¼ç”Ÿï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½å¯ä»¥é–‹ç™¼å‡ºæ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°æ‡‰å°é€™äº›å¥åº·å•é¡Œã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶æ”¹è‰¯å½¢å¼ï¼Œå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ½›åœ¨å·¥å…·ï¼Œé€™å°æ–¼æå‡æˆ‘å€‘çš„å¥åº·ç‹€æ…‹æœ‰è‘—é‡è¦çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©åœ¨èª¿ç¯€äººé¡æ¨¹çªç´°èƒå…ç–«åæ‡‰ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨é€™äº›åŒ–åˆç‰©ä¾†ä¿ƒé€²æ¨¹çªç´°èƒçš„è€å—æ€§ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶é›†ä¸­åœ¨è˜¿è””ç¡«ç´ èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çµåˆå¾Œï¼Œå°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒçš„å½±éŸ¿ï¼Œä¸¦æ¢è¨NFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç½®æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–å’Œè˜¿è””ç¡«ç´ -å‘‹å–ƒç³–é€²è¡Œè™•ç†ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›æ¨¹çªç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€å°Tç´°èƒçš„èª¿ç¯€èƒ½åŠ›ä»¥åŠNFATc1çš„ä¿¡è™Ÿå‚³å°ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒå½¢å¼çš„è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä¸¦ç¢ºèªNFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„é‡è¦æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å¤§äº†èª¿ç¯€æ€§Tç´°èƒçš„æ•¸é‡ï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œåªæœ‰è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èƒ½ä¿ƒé€²NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œé€™ä¸€éç¨‹åœ¨ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1å¾Œè¢«é˜»æ­¢ï¼Œé¡¯ç¤ºNFATc1åœ¨è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èª˜å°å…ç–«è€å—ä¸­çš„é—œéµä½œç”¨ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿç‰©è£¡çš„æˆåˆ†ï¼Œå¯èƒ½èƒ½å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç³»çµ±æ›´å¼·å¤§ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œé€™è½èµ·ä¾†å¯èƒ½æœ‰é»é™Œç”Ÿï¼Œä½†å®ƒåœ¨èª¿ç¯€æˆ‘å€‘èº«é«”çš„å…ç–«åæ‡‰ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚\n\né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„æ¨¹çªç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®å¹«åŠ©å…ç–«ç³»çµ±å·¥ä½œçš„ç´°èƒï¼‰ã€‚ä»–å€‘æŠŠé€™äº›ç´°èƒæ”¾åœ¨ä¸€å€‹æ¨¡æ“¬çš„ç‚ç—‡ç’°å¢ƒä¸­ï¼Œç„¶å¾Œç”¨è˜¿è””ç¡«ç´ åŠå…¶ä¸åŒå½¢å¼é€²è¡Œè™•ç†ï¼Œè§€å¯Ÿå®ƒå€‘çš„åæ‡‰ã€‚\n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ -ç”˜éœ²ç³–çš„çµ„åˆèƒ½æœ‰æ•ˆåœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿä¸€ç¨®è€å—æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå€‘èƒ½æ›´å¥½åœ°æ‡‰å°ç‚ç—‡ï¼Œä¸¦æ¸›å°‘ä¸å¿…è¦çš„å…ç–«åæ‡‰ã€‚é€™å°æ–¼æœªä¾†å¯èƒ½çš„æ²»ç™‚æ–¹æ³•éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒç‚ºæˆ‘å€‘æä¾›äº†é‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ–°æ–¹å‘ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼èª¿ç¯€å…ç–«ç´°èƒçš„åæ‡‰ã€‚\n2. ç‰¹å®šå½¢å¼çš„è˜¿è””ç¡«ç´ èƒ½ä¿ƒé€²å…ç–«è€å—æ€§ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†ç‚ç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ©Ÿæœƒï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main results of a study on a compound called sulforaphane. Include symbols for broccoli or sulforaphane, simplified illustrations of human cells, arrows or flow lines to indicate experimental steps, and a section labeled 'Main Results' showcasing protective effects or changes observed in the immune response.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç‚ç—‡ Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶é«˜å£“ç—‡å€™ç¾¤ï¼ˆTakotsubo syndrome, TTSï¼‰éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå®ƒå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚å› æ­¤ï¼Œäº†è§£å¦‚ä½•æ¸›è¼•é€™ç¨®ç—…ç—‡çš„å½±éŸ¿ï¼Œå°æ–¼å¿ƒè‡Ÿå¥åº·çš„ç¶­è­·éå¸¸é‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å¯èƒ½æˆç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œå› ç‚ºå®ƒèƒ½å¤ æ¸›å°‘èˆ‡TTSç›¸é—œçš„å¿ƒè‚Œæå‚·ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰å•Ÿç™¼æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨é«˜å£“ç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼ŒTTSçš„ç™¼ç—…æ©Ÿåˆ¶èˆ‡æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰æœ‰é—œï¼Œä½†ç›®å‰å°šç„¡é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ‰¾åˆ°ä¸€ç¨®é‡å°é€™äº›ç—…ç†éç¨‹çš„æ²»ç™‚æ‰‹æ®µï¼Œé€²è€Œæ”¹å–„TTSæ‚£è€…çš„é å¾Œã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ ï¼ˆisoproterenolï¼‰èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶å°æŠ—æ°§åŒ–èƒ½åŠ›çš„æå‡ã€ç·šç²’é«”æå‚·çš„æ¸›å°‘ä»¥åŠéµæ­»äº¡æ¨™è¨˜çš„æŠ‘åˆ¶ã€‚é€™äº›å¯¦é©—æ—¨åœ¨ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„TTSç›¸é—œçš„å¿ƒè‚Œæå‚·ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¢å¾©å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’ŒæŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ã€‚èˆ‡éµæ­»äº¡æŠ‘åˆ¶åŠ‘Fer-1é¡ä¼¼ï¼Œè˜¿è””ç¡«ç´ ä¹Ÿé™ä½äº†ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä½†å®ƒç¨ç‰¹åœ°æ¿€æ´»äº†Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶Nrf2æœƒæ¶ˆé™¤è˜¿è””ç¡«ç´ çš„ç›Šè™•ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºé›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶é«˜å£“ç—‡å€™ç¾¤ï¼ˆTakotsubo syndrome, TTSï¼‰éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå®ƒå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚å› æ­¤ï¼Œäº†è§£å¦‚ä½•æ¸›è¼•é€™ç¨®ç—…ç—‡çš„å½±éŸ¿ï¼Œå°æ–¼å¿ƒè‡Ÿå¥åº·çš„ç¶­è­·éå¸¸é‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å¯èƒ½æˆç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œå› ç‚ºå®ƒèƒ½å¤ æ¸›å°‘èˆ‡TTSç›¸é—œçš„å¿ƒè‚Œæå‚·ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰å•Ÿç™¼æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨é«˜å£“ç—‡å€™ç¾¤ï¼ˆTTSï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼ŒTTSçš„ç™¼ç—…æ©Ÿåˆ¶èˆ‡æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰æœ‰é—œï¼Œä½†ç›®å‰å°šç„¡é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ‰¾åˆ°ä¸€ç¨®é‡å°é€™äº›ç—…ç†éç¨‹çš„æ²»ç™‚æ‰‹æ®µï¼Œé€²è€Œæ”¹å–„TTSæ‚£è€…çš„é å¾Œã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ ï¼ˆisoproterenolï¼‰èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶å°æŠ—æ°§åŒ–èƒ½åŠ›çš„æå‡ã€ç·šç²’é«”æå‚·çš„æ¸›å°‘ä»¥åŠéµæ­»äº¡æ¨™è¨˜çš„æŠ‘åˆ¶ã€‚é€™äº›å¯¦é©—æ—¨åœ¨ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„TTSç›¸é—œçš„å¿ƒè‚Œæå‚·ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¢å¾©å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’ŒæŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ã€‚èˆ‡éµæ­»äº¡æŠ‘åˆ¶åŠ‘Fer-1é¡ä¼¼ï¼Œè˜¿è””ç¡«ç´ ä¹Ÿé™ä½äº†ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä½†å®ƒç¨ç‰¹åœ°æ¿€æ´»äº†Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶Nrf2æœƒæ¶ˆé™¤è˜¿è””ç¡«ç´ çš„ç›Šè™•ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºé›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“è˜¿è””ä¹Ÿèƒ½æˆç‚ºå¿ƒè‡Ÿå¥åº·çš„å°å¹«æ‰‹å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®åœ¨é’èŠ±æ¤°èœå’Œè˜¿è””ä¸­ç™¼ç¾çš„æˆåˆ†ï¼‰å¯èƒ½å°é«˜å£“ç—‡å€™ç¾¤ï¼ˆTTSï¼‰æœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼æ¢è¨TTSçš„ç™¼ç—…æ©Ÿåˆ¶ï¼Œç™¼ç¾å®ƒèˆ‡æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æœ‰é—œï¼Œè€Œç›®å‰é‚„æ²’æœ‰æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨äº†å°é¼ å’Œå¿ƒè‡Ÿç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¢å¾©å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚é€™è¡¨æ˜å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚TTSçš„ä¸€å€‹æ–°é¸æ“‡ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„å¿ƒè‡Ÿå¥åº·ï¼Œæ¢å¾©å¿ƒè‚ŒåŠŸèƒ½ã€‚  \n2. å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚  \n3. å¯èƒ½æˆç‚ºé«˜å£“ç—‡å€™ç¾¤çš„æ–°ç™‚æ³•ï¼  \n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒå¿ƒè‡Ÿå¥åº·ï¼Œæœªä¾†çš„ç ”ç©¶æˆ–è¨±æœƒå¸¶ä¾†æ›´å¤šé©šå–œï¼",
    "image_prompt": "Create a flat design infographic with a light background that illustrates the experiment and main findings of a study on sulforaphane. Include simplified icons for broccoli or radish to represent sulforaphane, simplified figures of mice and heart cells as experimental subjects, arrows or flow lines to show the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed in heart health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é«˜å£“ç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ™‚ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†ç›¸ç•¶å¤§çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·æœ‰ä¿è­·ä½œç”¨ï¼Œé€™æ„å‘³è‘—é€éé£²é£Ÿå¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½åœ¨ä¸€å®šç¨‹åº¦ä¸Šæ¸›å°‘é€™äº›æ¯’ç´ å°å¥åº·çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²è…¸é“å¥åº·ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£å®ƒå¦‚ä½•å½±éŸ¿è…¸é“ç´°èƒçš„å¥åº·ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ å’Œè±¬è…¸é“ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡C57BL/6é›„æ€§å°é¼ åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°å…¶ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡ä¼¼ç‰©ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªæª¢æ¸¬å’Œç´°èƒåˆ†æç­‰ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡å…¶å¢å¼·æº¶é…¶é«”é…¸åŒ–çš„èƒ½åŠ›æœ‰é—œï¼Œé€™æ˜¯ä¸€å€‹æ–°çš„æ©Ÿåˆ¶ã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ­ç¤ºæ›´å»£æ³›çš„ä¿è­·æ©Ÿåˆ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ™‚ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†ç›¸ç•¶å¤§çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·æœ‰ä¿è­·ä½œç”¨ï¼Œé€™æ„å‘³è‘—é€éé£²é£Ÿå¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½åœ¨ä¸€å®šç¨‹åº¦ä¸Šæ¸›å°‘é€™äº›æ¯’ç´ å°å¥åº·çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²è…¸é“å¥åº·ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£å®ƒå¦‚ä½•å½±éŸ¿è…¸é“ç´°èƒçš„å¥åº·ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ å’Œè±¬è…¸é“ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡C57BL/6é›„æ€§å°é¼ åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°å…¶ä¿è­·æ•ˆæœã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œå‰‡ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“å™¨å®˜é¡ä¼¼ç‰©ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªæª¢æ¸¬å’Œç´°èƒåˆ†æç­‰ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡å…¶å¢å¼·æº¶é…¶é«”é…¸åŒ–çš„èƒ½åŠ›æœ‰é—œï¼Œé€™æ˜¯ä¸€å€‹æ–°çš„æ©Ÿåˆ¶ã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ­ç¤ºæ›´å»£æ³›çš„ä¿è­·æ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘æ¯å¤©åƒçš„é£Ÿç‰©è£¡ï¼Œå¯èƒ½éš±è—è‘—ä¸€äº›è®“è…¸é“ä¸èˆ’æœçš„æ±è¥¿ï¼é€™æ¬¡çš„ç ”ç©¶å°±é—œæ³¨äº†ä¸€ç¨®å«åšè„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰çš„éœ‰èŒæ¯’ç´ ï¼Œå®ƒåœ¨å¾ˆå¤šé£Ÿç‰©ä¸­éƒ½èƒ½æ‰¾åˆ°ï¼Œå°æˆ‘å€‘çš„å¥åº·å¯ä¸æ˜¯å¥½æ¶ˆæ¯ã€‚ä¸éï¼Œç ”ç©¶ç™¼ç¾ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ä¼¼ä¹èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—é€™ç¨®æ¯’ç´ å¸¶ä¾†çš„è…¸é“æå‚·ã€‚ \n\né€™é …ç ”ç©¶çš„åœ˜éšŠä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œå¯¦é©—ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„è…¸é“çš„å¥åº·ï¼Œé‚„æœ‰åŠ©æ–¼æ¸›å°‘ç”±DONå¼•èµ·çš„ç´°èƒæ­»äº¡å’Œæ°§åŒ–å£“åŠ›ã€‚é€™æ˜¯å› ç‚ºè˜¿è””ç¡«ç´ èƒ½ä¿ƒé€²ç´°èƒå…§çš„é…¸åŒ–éç¨‹ï¼Œé€™æ˜¯ä¸€å€‹æ–°ç™¼ç¾çš„ä¿è­·æ©Ÿåˆ¶ï¼ \n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘éœ‰èŒæ¯’ç´ å°è…¸é“çš„æå®³ã€‚\n2. é€™é …ç ”ç©¶ä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒä¾†é©—è­‰æ•ˆæœã€‚\n3. è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡ä¿ƒé€²ç´°èƒé…¸åŒ–æœ‰é—œï¼Œé€™æ˜¯æ–°çš„ç ”ç©¶æ–¹å‘ï¼\n\nå¤šåƒé’èŠ±æ¤°èœï¼Œè®“è…¸é“æ›´å¥åº·å§ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on sulforaphane (SFN) and its protective effects against deoxynivalenol (DON) toxicity. The image should include simplified icons of broccoli or vegetables representing sulforaphane, experimental subjects like mice and intestinal cells, and arrows or flow lines indicating the steps of the experiment. Additionally, include a section labeled 'Main Results' that highlights key findings such as protective effects and improvements in intestinal health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æé«˜ç´°èƒæŠµæŠ—å£“åŠ›çš„èƒ½åŠ›ï¼Œå¾è€Œæ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„æœ‰å®³å½±éŸ¿ã€‚é€™å°æ–¼å¸Œæœ›æ¸›å°‘å¸ç…™å°å¥åº·å½±éŸ¿çš„äººä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿SIRT1é€™å€‹åŸºå› çš„è¡¨é”ï¼Œå› ç‚ºSIRT1åœ¨ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œç”Ÿå­˜ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™å°äººé«”æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„æå®³ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€éMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œå‰‡ä½¿ç”¨äº†å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿå…¶çµ„ç¹”å­¸è®ŠåŒ–ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿åŠNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æé«˜ç´°èƒæŠµæŠ—å£“åŠ›çš„èƒ½åŠ›ï¼Œå¾è€Œæ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„æœ‰å®³å½±éŸ¿ã€‚é€™å°æ–¼å¸Œæœ›æ¸›å°‘å¸ç…™å°å¥åº·å½±éŸ¿çš„äººä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿SIRT1é€™å€‹åŸºå› çš„è¡¨é”ï¼Œå› ç‚ºSIRT1åœ¨ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œç”Ÿå­˜ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™å°äººé«”æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„æå®³ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€éMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œå‰‡ä½¿ç”¨äº†å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿå…¶çµ„ç¹”å­¸è®ŠåŒ–ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿åŠNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³å¯ä¸æ˜¯å°äº‹ï¼Œä½†ä½ çŸ¥é“è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæˆ‘å€‘çš„å®ˆè­·è€…å—ï¼Ÿé€™é …ç ”ç©¶è®“æˆ‘å€‘å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰äº†æ–°å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚\n\nç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®å«åšSIRT1çš„åŸºå› ï¼Œé€™å€‹åŸºå› åœ¨ç´°èƒæŠµæŠ—å£“åŠ›å’Œå­˜æ´»ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚ä»–å€‘ä½¿ç”¨äº†äººé¡æ°£é“ç´°èƒå’Œå°é¼ ä¾†é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©é€ æˆçš„è‚ºéƒ¨æå®³çš„ä¿è­·æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§å’Œè€åŒ–ï¼Œä¸¦æ”¹å–„å°é¼ çš„è‚ºéƒ¨è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œå®ƒé‚„èƒ½é€†è½‰ä¸€äº›ä¸è‰¯åŸºå› çš„è®ŠåŒ–ï¼Œæ¸›å°‘å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€‚\n\nğŸ¤” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„æå®³ã€‚\n2. å®ƒèƒ½æ”¹å–„ç´°èƒçš„æŠµæŠ—åŠ›ï¼Œæ¸›å°‘è€åŒ–ç¾è±¡ã€‚\n3. è˜¿è””ç¡«ç´ åœ¨å°æŠ—æ°§åŒ–å£“åŠ›æ–¹é¢é¡¯ç¤ºå‡ºæ½›åŠ›ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒå¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹ï¼",
    "image_prompt": "Create an informative illustration that explains the experimental methods and main results of a study on the protective effects of sulforaphane against smoking-induced lung damage. Use a flat design style with a light-colored background. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, and cells), arrows or flow lines to indicate the experimental steps, and a section clearly labeled 'Main Results' showcasing protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦æ„ç¾©ã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå°‡æœ‰åŠ©æ–¼æå‡ç”Ÿæ´»å“è³ªï¼Œä¸¦å¯èƒ½æ¸›å°‘å› çš®è†šè€åŒ–è€Œå¼•ç™¼çš„ç›¸é—œå¥åº·å•é¡Œã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ï¼Œä½†å…¶åœ¨çš®è†šè€åŒ–æ–¹é¢çš„å…·é«”æ•ˆæœå°šæœªæ˜ç¢ºã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ä¾†æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾å‡ºå¯èƒ½çš„æŠ—è€åŒ–ç›®æ¨™ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†æ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œå°51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„è˜¿è””ç¡«ç´ ç›®æ¨™é€²è¡Œäº†è­˜åˆ¥ã€‚å¯¦é©—å°è±¡ç‚º18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ ï¼Œç ”ç©¶è€…åœ¨é€™äº›å°é¼ ä¸­è£œå……è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ï¼ŒæŒçºŒæ™‚é–“ç‚º2å€‹æœˆã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦é€éæ´»åŒ–apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆã€‚ç ”ç©¶ä¸­è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªï¼Œé€™äº›è›‹ç™½è³ªçš„ä¸Šèª¿èˆ‡è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯†åˆ‡ç›¸é—œã€‚æ­¤å¤–ï¼Œå…ç–«ç´°èƒçš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘çš®è†šçµ„ç¹”ä¸­Tç´°èƒçš„è€—ç«­ï¼Œé€™é€²ä¸€æ­¥æ”¯æŒäº†å…¶åœ¨å°æŠ—å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦æ„ç¾©ã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå°‡æœ‰åŠ©æ–¼æå‡ç”Ÿæ´»å“è³ªï¼Œä¸¦å¯èƒ½æ¸›å°‘å› çš®è†šè€åŒ–è€Œå¼•ç™¼çš„ç›¸é—œå¥åº·å•é¡Œã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ï¼Œä½†å…¶åœ¨çš®è†šè€åŒ–æ–¹é¢çš„å…·é«”æ•ˆæœå°šæœªæ˜ç¢ºã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ä¾†æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾å‡ºå¯èƒ½çš„æŠ—è€åŒ–ç›®æ¨™ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†æ•´åˆæ€§ç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œå°51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„è˜¿è””ç¡«ç´ ç›®æ¨™é€²è¡Œäº†è­˜åˆ¥ã€‚å¯¦é©—å°è±¡ç‚º18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ ï¼Œç ”ç©¶è€…åœ¨é€™äº›å°é¼ ä¸­è£œå……è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ï¼ŒæŒçºŒæ™‚é–“ç‚º2å€‹æœˆã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦é€éæ´»åŒ–apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆã€‚ç ”ç©¶ä¸­è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªï¼Œé€™äº›è›‹ç™½è³ªçš„ä¸Šèª¿èˆ‡è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯†åˆ‡ç›¸é—œã€‚æ­¤å¤–ï¼Œå…ç–«ç´°èƒçš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘çš®è†šçµ„ç¹”ä¸­Tç´°èƒçš„è€—ç«­ï¼Œé€™é€²ä¸€æ­¥æ”¯æŒäº†å…¶åœ¨å°æŠ—å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿå¹´é½¡å¢é•·ä¸åƒ…å½±éŸ¿æˆ‘å€‘çš„èº«é«”ï¼Œé‚„æœƒè®“çš®è†šè®Šå¾—è„†å¼±ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾è˜¿è””ä¸­æå–çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå·²ç¶“åœ¨ç™Œç—‡æ²»ç™‚ä¸­æœ‰ä¸å°‘æ‡‰ç”¨ï¼Œä½†å°æ–¼çš®è†šè€åŒ–çš„å…·é«”æ•ˆæœå»é‚„ä¸å¤ªæ¸…æ¥šã€‚\n\né€™é …ç ”ç©¶ä½¿ç”¨äº†18å€‹æœˆå¤§çš„å°é¼ ï¼Œé€™äº›å°é¼ åœ¨å¯¦é©—ä¸­è£œå……äº†è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†å®ƒå°çš®è†šçµæ§‹å’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼ŒæŒçºŒäº†å…©å€‹æœˆã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…é¡¯è‘—æ”¹å–„äº†çš®è†šçš„å½¢æ…‹ï¼Œé‚„å¢å¼·äº†å…ç–«åŠŸèƒ½ï¼\n\nç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€éæ´»åŒ–æŸäº›ä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœï¼Œä¸¦ä¸”é™ä½äº†çš®è†šä¸­æŸäº›å…ç–«ç´°èƒçš„è€—ç«­ï¼Œé€™æ¨£çš„ç™¼ç¾è®“æˆ‘å€‘å°æŠ—å…§åœ¨çš®è†šè€åŒ–çš„æ½›åŠ›å……æ»¿æœŸå¾…ã€‚\n\nç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½å¢å¼·çš®è†šçš„å…ç–«åŠŸèƒ½ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on the effects of sulforaphane on skin aging. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells. Use arrows or flow lines to show the experimental process. Include a section labeled 'Main Results' highlighting protective effects and changes observed in skin structure and immune function. Use a light background with soft colors for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å’Œæ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“ç‰©å°å¥åº·å½±éŸ¿çš„å¢åŠ ï¼Œäº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†æ¸›å°‘é€™äº›å½±éŸ¿ï¼Œå°‡å°å…¬å…±å¥åº·æœ‰é‡è¦çš„è²¢ç»ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±è¡¡çš„ä¿è­·ä½œç”¨ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå‚·å®³ï¼Œå› æ­¤ç ”ç©¶å…¶å°å¥åº·çš„å½±éŸ¿ä»¥åŠå¦‚ä½•é€éè˜¿è””ç¡«ç´ ä¾†ç·©è§£é€™äº›å½±éŸ¿ï¼Œæˆç‚ºäº†é€™é …ç ”ç©¶çš„é‡é»ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„å’Œ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨ç‚ºæœŸ8é€±çš„å¯¦é©—ä¸­æ¥å—ä¸åŒçš„è™•ç†ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è‚è‡ŸåŠŸèƒ½ã€å…ç–«åæ‡‰ä»¥åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†åŸºå› è¡¨é”å’Œè½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«åŠŸèƒ½ï¼Œè€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›ä¸è‰¯å½±éŸ¿ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½è‚è‡Ÿä¸­çš„è†½é…¸ç©ç´¯ï¼Œæ¢å¾©åŸºå› è¡¨é”çš„æ­£å¸¸æ°´å¹³ï¼Œä¸¦æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œé€™äº›è®ŠåŒ–å¯èƒ½æœ‰åŠ©æ–¼æ¢å¾©ä»£è¬å¹³è¡¡å’Œå…ç–«åŠŸèƒ½ã€‚é€™äº›ç™¼ç¾æä¾›äº†æ–°çš„è¦‹è§£ï¼Œèªªæ˜äº†ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æ©Ÿåˆ¶ï¼Œä¸¦å±•ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å’Œæ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“ç‰©å°å¥åº·å½±éŸ¿çš„å¢åŠ ï¼Œäº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†æ¸›å°‘é€™äº›å½±éŸ¿ï¼Œå°‡å°å…¬å…±å¥åº·æœ‰é‡è¦çš„è²¢ç»ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±è¡¡çš„ä¿è­·ä½œç”¨ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå‚·å®³ï¼Œå› æ­¤ç ”ç©¶å…¶å°å¥åº·çš„å½±éŸ¿ä»¥åŠå¦‚ä½•é€éè˜¿è””ç¡«ç´ ä¾†ç·©è§£é€™äº›å½±éŸ¿ï¼Œæˆç‚ºäº†é€™é …ç ”ç©¶çš„é‡é»ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„å’Œ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨ç‚ºæœŸ8é€±çš„å¯¦é©—ä¸­æ¥å—ä¸åŒçš„è™•ç†ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è‚è‡ŸåŠŸèƒ½ã€å…ç–«åæ‡‰ä»¥åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†åŸºå› è¡¨é”å’Œè½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«åŠŸèƒ½ï¼Œè€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›ä¸è‰¯å½±éŸ¿ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½è‚è‡Ÿä¸­çš„è†½é…¸ç©ç´¯ï¼Œæ¢å¾©åŸºå› è¡¨é”çš„æ­£å¸¸æ°´å¹³ï¼Œä¸¦æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œé€™äº›è®ŠåŒ–å¯èƒ½æœ‰åŠ©æ–¼æ¢å¾©ä»£è¬å¹³è¡¡å’Œå…ç–«åŠŸèƒ½ã€‚é€™äº›ç™¼ç¾æä¾›äº†æ–°çš„è¦‹è§£ï¼Œèªªæ˜äº†ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æ©Ÿåˆ¶ï¼Œä¸¦å±•ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„è”¬èœï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±æœ‰å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯è˜¿è””ä¸­çš„ä¸€ç¨®æˆåˆ†ï¼‰å°ç’°å¢ƒæ±¡æŸ“ç‰©ä¸‰è‹¯éŒ«çš„å½±éŸ¿ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®æœƒå‚·å®³æˆ‘å€‘èº«é«”çš„æ±¡æŸ“ç‰©ï¼Œç ”ç©¶è€…æƒ³çŸ¥é“è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©æ¸›å°‘å®ƒé€ æˆçš„å‚·å®³ã€‚  \n  åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ç”¨é¯‰é­šä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡å®ƒå€‘åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥æ˜¯æ²’æœ‰æ±¡æŸ“çš„å°ç…§çµ„ã€åªæ¥è§¸ä¸‰è‹¯éŒ«çš„çµ„å’Œæ¥è§¸ä¸‰è‹¯éŒ«ä½†é‚„åŠ äº†è˜¿è””ç¡«ç´ çš„çµ„ã€‚ç¶“éå…«é€±çš„è§€å¯Ÿï¼Œç ”ç©¶è€…ç™¼ç¾ï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦å°é­šçš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±é€ æˆäº†æå®³ï¼Œä½†è˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¹«åŠ©æ¸›å°‘é€™äº›ä¸è‰¯å½±éŸ¿ï¼  \n  ä¸»è¦ç™¼ç¾åŒ…æ‹¬ï¼š  \n  - è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘è‚è‡Ÿä¸­çš„æ¯’ç´ ç©ç´¯  \n  - æœ‰åŠ©æ–¼æ¢å¾©æ­£å¸¸çš„å…ç–«åŠŸèƒ½  \n  - æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆ  \n  é€™äº›çµæœè®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éé£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ï¼Œæˆ–è¨±èƒ½å°æŠ—ç’°å¢ƒä¸­çš„æœ‰å®³ç‰©è³ªï¼ŒçœŸæ˜¯å¤ªç¥å¥‡äº†ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on the protective effects of sulforaphane from radishes against the toxicity of tributyltin. Include simplified icons of radishes or broccoli, fish as experimental subjects, and arrows or flow lines to indicate the experimental steps. Highlight a section labeled 'Main Results' showcasing the protective effects and changes observed, using a flat design style with a white or light-colored background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼ç”Ÿã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„åŠŸèƒ½ï¼Œé€™å°æ–¼é é˜²å’Œæ²»ç™‚ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œæ”¹å–„ä»£è¬ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚è…¸é“ç–¾ç—…çš„æ–°é¸æ“‡ï¼Œé€™è®“æˆ‘å€‘å°è…¸é“å¥åº·çš„ç¶­è­·æœ‰äº†æ–°çš„æ€è€ƒã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œç›¸é—œçš„ä»£è¬éç¨‹ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤ä¾†æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—…ç†ç‹€æ³ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ¢ç´¢è˜¿è””ç¡«ç´ çš„æŠ—ç‚ä½œç”¨åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†æ¨¡æ“¬è…¸é“ç‚ç—‡ã€‚ç ”ç©¶è€…çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸çš„ç‚ç—‡ç¨‹åº¦ã€‚ç ”ç©¶é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°å¾®ç”Ÿç‰©çµ„æˆçš„å½±éŸ¿ï¼Œä¸¦é€éä»£è¬çµ„å­¸åˆ†æä¾†äº†è§£ç›¸é—œçš„ä»£è¬è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆä¹Ÿå¾—åˆ°äº†èª¿æ•´ï¼Œç‰¹å®šçš„å¾®ç”Ÿç‰©å¦‚Turicibacterã€Lactobacilluså’ŒBacteroidesçš„æ¯”ä¾‹ç™¼ç”Ÿäº†è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™äº›çµæœè¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬ä¾†æ¸›è¼•è…¸é“ç‚ç—‡ï¼Œé€™ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„è¦‹è§£ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼ç”Ÿã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„åŠŸèƒ½ï¼Œé€™å°æ–¼é é˜²å’Œæ²»ç™‚ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œæ”¹å–„ä»£è¬ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚è…¸é“ç–¾ç—…çš„æ–°é¸æ“‡ï¼Œé€™è®“æˆ‘å€‘å°è…¸é“å¥åº·çš„ç¶­è­·æœ‰äº†æ–°çš„æ€è€ƒã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œç›¸é—œçš„ä»£è¬éç¨‹ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤ä¾†æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—…ç†ç‹€æ³ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ¢ç´¢è˜¿è””ç¡«ç´ çš„æŠ—ç‚ä½œç”¨åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†æ¨¡æ“¬è…¸é“ç‚ç—‡ã€‚ç ”ç©¶è€…çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸çš„ç‚ç—‡ç¨‹åº¦ã€‚ç ”ç©¶é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°å¾®ç”Ÿç‰©çµ„æˆçš„å½±éŸ¿ï¼Œä¸¦é€éä»£è¬çµ„å­¸åˆ†æä¾†äº†è§£ç›¸é—œçš„ä»£è¬è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆä¹Ÿå¾—åˆ°äº†èª¿æ•´ï¼Œç‰¹å®šçš„å¾®ç”Ÿç‰©å¦‚Turicibacterã€Lactobacilluså’ŒBacteroidesçš„æ¯”ä¾‹ç™¼ç”Ÿäº†è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™äº›çµæœè¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬ä¾†æ¸›è¼•è…¸é“ç‚ç—‡ï¼Œé€™ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„è¦‹è§£ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åƒ…åƒ…æ˜¯é¤æ¡Œä¸Šçš„é…èœï¼Œå®ƒé‚„å¯èƒ½å°æˆ‘å€‘çš„è…¸é“å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœï¼Œè®“æˆ‘å€‘çš„è…¸é“æ›´å¥åº·ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚é€™ç¨®æ…¢æ€§è…¸é“ç–¾ç—…ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…ç”¨ç‰¹å®šçš„æ–¹æ³•æ¨¡æ“¬è…¸é“ç‚ç—‡ï¼Œç„¶å¾Œçµ¦å°é¼ é¤µé£Ÿè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒå°è…¸é“çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œé‚„èƒ½æ¸›å°‘ç‚ç—‡ï¼Œä¸¦ä¸”èª¿æ•´è…¸é“å…§çš„å¾®ç”Ÿç‰©çµ„æˆã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚\n2. å®ƒèƒ½æ¢å¾©è…¸é“å±éšœï¼Œæ¸›å°‘ç‚ç—‡ã€‚\n3. èª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆï¼Œé€™å°å¥åº·æœ‰ç›Šã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è…¸é“å¥åº·æœ‰äº†æ–°çš„æ€è€ƒï¼Œæˆ–è¨±æœªä¾†è˜¿è””ç¡«ç´ æœƒæˆç‚ºæ²»ç™‚è…¸é“ç–¾ç—…çš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on daikon sulforaphane. Include symbols representing daikon or sulforaphane, simplified illustrations of experimental subjects like mice, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed in gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¯èƒ½å°æŠ—è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œä½¿ç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼ˆSFN-NLPsï¼‰èƒ½æ›´æœ‰æ•ˆåœ°ç™¼æ®ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œé€éæ”¹é€²è—¥ç‰©çš„ç©©å®šæ€§å’Œé‡‹æ”¾æ–¹å¼ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡æ²»ç™‚æ•ˆæœï¼Œé€²è€Œå°æŠ—ç™Œç—‡åŠç›¸é—œçš„ç‚ç—‡åæ‡‰ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œå°¤å…¶æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ã€‚é€éä½¿ç”¨ä¸åŒçš„å¯¦é©—çµ„ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åŠå…¶ç´ç±³è„‚è³ªé«”å½¢å¼åœ¨æŠ—ç™Œéç¨‹ä¸­çš„ä½œç”¨ï¼Œä¸¦æ¢ç´¢å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€ä»¥åŠå¸¶æœ‰EACçš„è…«ç˜¤çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œä¸¦è§€å¯Ÿè…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œç”Ÿç‰©æ¨™è¨˜çš„è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†æ–¹å¼çš„æ•ˆæœï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤ä¸­çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œè¡¨ç¾å‡ºé¡¯è‘—çš„æ•ˆæœï¼Œä¸¦ä¸”æ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´èƒ½å»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æœ‰æ•ˆèª¿ç¯€é—œéµçš„åˆ†å­é€šè·¯ï¼ŒæŠ‘åˆ¶ç‚ç—‡åŸºå› çš„è¡¨é”ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨ä¿è­·è‚è‡Ÿå®Œæ•´æ€§æ–¹é¢ä¹Ÿæœ‰è‰¯å¥½çš„æ•ˆæœï¼Œé€™äº›ç™¼ç¾å¼·èª¿äº†å…¶åœ¨æŠ—è…«ç˜¤åŠæŠ—ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¯èƒ½å°æŠ—è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œä½¿ç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ ï¼ˆSFN-NLPsï¼‰èƒ½æ›´æœ‰æ•ˆåœ°ç™¼æ®ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œé€éæ”¹é€²è—¥ç‰©çš„ç©©å®šæ€§å’Œé‡‹æ”¾æ–¹å¼ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡æ²»ç™‚æ•ˆæœï¼Œé€²è€Œå°æŠ—ç™Œç—‡åŠç›¸é—œçš„ç‚ç—‡åæ‡‰ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œå°¤å…¶æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ã€‚é€éä½¿ç”¨ä¸åŒçš„å¯¦é©—çµ„ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åŠå…¶ç´ç±³è„‚è³ªé«”å½¢å¼åœ¨æŠ—ç™Œéç¨‹ä¸­çš„ä½œç”¨ï¼Œä¸¦æ¢ç´¢å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€ä»¥åŠå¸¶æœ‰EACçš„è…«ç˜¤çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œä¸¦è§€å¯Ÿè…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œç”Ÿç‰©æ¨™è¨˜çš„è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†æ–¹å¼çš„æ•ˆæœï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ åœ¨æŠ—è…«ç˜¤ä¸­çš„æ½›åŠ›ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œè¡¨ç¾å‡ºé¡¯è‘—çš„æ•ˆæœï¼Œä¸¦ä¸”æ¯”å–®ç¨ä½¿ç”¨è˜¿è””ç¡«ç´ æ›´èƒ½å»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æœ‰æ•ˆèª¿ç¯€é—œéµçš„åˆ†å­é€šè·¯ï¼ŒæŠ‘åˆ¶ç‚ç—‡åŸºå› çš„è¡¨é”ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨ä¿è­·è‚è‡Ÿå®Œæ•´æ€§æ–¹é¢ä¹Ÿæœ‰è‰¯å¥½çš„æ•ˆæœï¼Œé€™äº›ç™¼ç¾å¼·èª¿äº†å…¶åœ¨æŠ—è…«ç˜¤åŠæŠ—ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å¤§å®¶çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™ç¨®æˆåˆ†å¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°ä¸€ç¨®ç™Œç—‡çš„å½±éŸ¿ï¼Œç ”ç©¶è€…å€‘æƒ³äº†è§£å®ƒæ˜¯å¦‚ä½•æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·çš„ã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘ä½¿ç”¨äº†90éš»å°é¼ ï¼Œåˆ†æˆä¸åŒçš„çµ„åˆ¥ä¾†æ¸¬è©¦è˜¿è””ç¡«ç´ åŠå…¶æ–°å‹ç´ç±³è„‚è³ªé«”ï¼ˆé€™æ˜¯ä¸€ç¨®åŒ…è£¹è—¥ç‰©çš„æ–¹å¼ï¼‰ã€‚\n\nç¶“é20å¤©çš„è§€å¯Ÿï¼Œç ”ç©¶è€…ç™¼ç¾ä½¿ç”¨ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œå»¶é•·å°é¼ å­˜æ´»æ™‚é–“æ–¹é¢è¡¨ç¾å¾—æ›´å¥½ï¼Œç”šè‡³èƒ½æœ‰æ•ˆèª¿ç¯€èˆ‡ç‚ç—‡æœ‰é—œçš„åŸºå› ï¼Œè®“ç´°èƒå‡‹äº¡ï¼ˆæ­»äº¡ï¼‰è®Šå¾—æ›´å®¹æ˜“ï¼é€™äº›ç™¼ç¾è®“äººæœŸå¾…æœªä¾†åœ¨ç™Œç—‡æ²»ç™‚ä¸Šçš„æ‡‰ç”¨ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—è…«ç˜¤ç”Ÿé•·ã€‚\n2. ä½¿ç”¨ç´ç±³è„‚è³ªé«”çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´ä½³ã€‚\n3. ç ”ç©¶é¡¯ç¤ºå®ƒæœ‰åŠ©æ–¼èª¿ç¯€ç‚ç—‡åæ‡‰ï¼Œä¿è­·è‚è‡Ÿå¥åº·ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experimental method and main results of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines depicting the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½ç‚ºèƒƒç™Œæ‚£è€…å¸¶ä¾†æ–°çš„å¸Œæœ›ï¼Œä¸¦ä¿ƒé€²æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚ç­–ç•¥ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„åˆ†å­æ©Ÿåˆ¶ï¼Œä»¥ä¾¿ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›æ–°çš„è¦‹è§£ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§çµ„ä»¶ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¸”èˆ‡CKMT2-AS1çš„è¡¨é”æœ‰é—œã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚é€²ä¸€æ­¥çš„æ©Ÿåˆ¶ç ”ç©¶ç™¼ç¾ï¼ŒSTAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè€Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ åœ¨èƒƒç™Œæ²»ç™‚ä¸­çš„æ½›åŠ›æä¾›äº†æ–°çš„è¦‹è§£ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½ç‚ºèƒƒç™Œæ‚£è€…å¸¶ä¾†æ–°çš„å¸Œæœ›ï¼Œä¸¦ä¿ƒé€²æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚ç­–ç•¥ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„åˆ†å­æ©Ÿåˆ¶ï¼Œä»¥ä¾¿ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›æ–°çš„è¦‹è§£ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§çµ„ä»¶ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¸”èˆ‡CKMT2-AS1çš„è¡¨é”æœ‰é—œã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚é€²ä¸€æ­¥çš„æ©Ÿåˆ¶ç ”ç©¶ç™¼ç¾ï¼ŒSTAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè€Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚é€™äº›ç™¼ç¾ç‚ºè˜¿è””ç¡«ç´ åœ¨èƒƒç™Œæ²»ç™‚ä¸­çš„æ½›åŠ›æä¾›äº†æ–°çš„è¦‹è§£ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿèƒƒç™Œæ˜¯å…¨çƒå¥åº·çš„ä¸€å¤§æŒ‘æˆ°ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ï¼Œè®“è¨±å¤šæ‚£è€…æ„Ÿåˆ°ç„¡åŠ©ã€‚ä¸éï¼Œæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†èƒƒç™Œæ²»ç™‚çš„æ–°å¸Œæœ›ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼‰å°èƒƒç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡é€²è¡Œäº†å¤šç¨®å¯¦é©—ï¼Œæƒ³è¦äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå®ƒèƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚\n\nä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¸”èˆ‡ä¸€ç¨®åç‚ºCKMT2-AS1çš„åˆ†å­è¡¨é”æœ‰é—œã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½ç›´æ¥å¹²æ“¾ä¸€å€‹å«STAT3çš„è›‹ç™½è³ªï¼Œé€²è€Œé™ä½ç™Œç´°èƒçš„æ´»æ€§ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œæ²»ç™‚ä¸­çš„æ½›åŠ›æœ‰äº†æ–°çš„èªè­˜ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£  \n2. CKMT2-AS1èˆ‡æ‚£è€…ç”Ÿå­˜ç‡æœ‰é—œ  \n3. STAT3è›‹ç™½è³ªæ˜¯è˜¿è””ç¡«ç´ çš„ä½œç”¨ç›®æ¨™  \n\né€™æˆ–è¨±èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚é–‹å•Ÿæ–°çš„å¤§é–€ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of the study on sulforaphane and stomach cancer. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like human cells or animals, and arrows or flow lines to indicate the steps of the experiment. Add a section that highlights the main results, such as protective effects or changes observed. Use a flat design style with a white or light-colored background and soft color palette.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰æ–¹é¢æœ‰æ½›åŠ›ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚é›–ç„¶ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»æœ‰çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶æä¾›äº†æ–°çš„è­‰æ“šï¼Œé¡¯ç¤ºå®ƒå¯èƒ½æˆç‚ºè‡ªé–‰ç—‡æ²»ç™‚çš„ä¸€å€‹è¼”åŠ©é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ä¸Šã€‚é€™å°æ–¼å°‹æ±‚æ›¿ä»£ç™‚æ³•çš„å®¶åº­ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä¸¦ä¸”é€²ä¸€æ­¥åˆ†æå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚ç”±æ–¼è‡ªé–‰ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¸€ç›´æ˜¯é†«å­¸ç•Œçš„é‡è¦èª²é¡Œï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥æœ‰é‡è¦å½±éŸ¿ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨çµ±è¨ˆè»Ÿé«”é€²è¡Œäº†ç¶œåˆåˆ†æã€‚é€™é …ç ”ç©¶ç´å…¥äº†å…­é …è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰ï¼Œä»¥æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´æ·±å…¥åœ°äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‡ªé–‰ç—‡çš„ç›¸é—œç”Ÿç‰©é€”å¾‘ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯æœ‰é—œã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œæˆç‚ºè‡ªé–‰ç—‡çš„ä¸€ç¨®å®‰å…¨è¼”åŠ©ç™‚æ³•ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰æ–¹é¢æœ‰æ½›åŠ›ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚é›–ç„¶ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»æœ‰çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶æä¾›äº†æ–°çš„è­‰æ“šï¼Œé¡¯ç¤ºå®ƒå¯èƒ½æˆç‚ºè‡ªé–‰ç—‡æ²»ç™‚çš„ä¸€å€‹è¼”åŠ©é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ä¸Šã€‚é€™å°æ–¼å°‹æ±‚æ›¿ä»£ç™‚æ³•çš„å®¶åº­ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä¸¦ä¸”é€²ä¸€æ­¥åˆ†æå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚ç”±æ–¼è‡ªé–‰ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¸€ç›´æ˜¯é†«å­¸ç•Œçš„é‡è¦èª²é¡Œï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥æœ‰é‡è¦å½±éŸ¿ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨çµ±è¨ˆè»Ÿé«”é€²è¡Œäº†ç¶œåˆåˆ†æã€‚é€™é …ç ”ç©¶ç´å…¥äº†å…­é …è©¦é©—ï¼Œå…±æœ‰333ååƒèˆ‡è€…ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰ï¼Œä»¥æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´æ·±å…¥åœ°äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‡ªé–‰ç—‡çš„ç›¸é—œç”Ÿç‰©é€”å¾‘ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯æœ‰é—œã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œæˆç‚ºè‡ªé–‰ç—‡çš„ä¸€ç¨®å®‰å…¨è¼”åŠ©ç™‚æ³•ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶å¯èƒ½è—è‘—å¹«åŠ©è‡ªé–‰ç—‡å­©å­çš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæˆ–è¨±èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰æ‰€å¹«åŠ©ã€‚\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ¢ç´¢è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚ç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­é¸å–äº†å…­é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æœ‰333ååƒèˆ‡è€…ï¼Œä¸¦é‹ç”¨å„ç¨®ç§‘å­¸æ–¹æ³•ä¾†åˆ†æè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—æ”¹å–„ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰äº†æå‡ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ï¼Œè®“äººæ„Ÿåˆ°å®‰å¿ƒã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚  \n2. ç ”ç©¶ä¸­æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„å‰¯ä½œç”¨ã€‚  \n3. é€™é …ç ”ç©¶æˆ–è¨±ç‚ºè‡ªé–‰ç—‡æ²»ç™‚æä¾›äº†ä¸€å€‹æ–°çš„è¼”åŠ©é¸æ“‡ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªå…¶æ•ˆæœã€‚",
    "image_prompt": "Create an infographic that illustrates the experiment methods and main results of a study on sulforaphane. The image should have a simple, flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experiment subjects like people or cells, arrows or flow lines showing the experimental steps, and a section clearly labeled 'Main Results' that highlights protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨å¥½è™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚äº†è§£é€™äº›ç‰¹æ€§å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å™¨å®˜ç§»æ¤çš„æˆåŠŸç‡ï¼Œä¸¦ç‚ºæœªä¾†çš„å¥åº·ç®¡ç†æä¾›æ–°çš„æ€è·¯ï¼Œç‰¹åˆ¥æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„ç—…äººä¸­ï¼Œå¦‚ä½•æ¸›å°‘æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œé€²è€Œæé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ï¼Œä¸¦ä¸”æ¢ç´¢å°‡å…¶èˆ‡ç†±æ•èšåˆç‰©æ°´å‡è† çµåˆçš„æ–¹å¼ï¼Œä»¥æé«˜å…¶ç™‚æ•ˆå’Œå¯ç”¨æ€§ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæ”¹å–„ç§»æ¤æ‰‹è¡“å¾Œçš„ç—…äººé å¾Œæä¾›æ–°çš„æ–¹æ³•ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œç‰¹åˆ¥æ˜¯å°‡ä¾›é«”çš„çš®è†šå¾Balb/cå°é¼ ç§»æ¤åˆ°C57BL/6å°é¼ èº«ä¸Šã€‚ç‚ºäº†æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œä»–å€‘é–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†ç›¸é—œçš„ç´°èƒæ¯’æ€§æ¸¬è©¦ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒè™•ç†çµ„åˆ¥çš„ç§»æ¤çµæœï¼Œä¸¦åˆ†æäº†å…ç–«ç´°èƒçš„æ´»åŒ–æƒ…æ³ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ ï¼Œå…¶ç§»æ¤çš®è†šçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ä»¥ä¸Šï¼Œä¸¦ä¸”åœ¨14å¤©å…§ä¿æŒè‰¯å¥½ç‹€æ…‹ã€‚èˆ‡æœªè™•ç†çš„å°é¼ ç›¸æ¯”ï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨çš®è†šçµ„ç¹”ä¸­ç™¼ç¾è¼ƒä½çš„ç™¼ç‚ç´°èƒæ•¸é‡ï¼Œé¡¯ç¤ºå‡ºå…ç–«åæ‡‰çš„æ¸›å°‘ã€‚æ­¤å¤–ï¼Œæµå¼ç´°èƒå„€çš„åˆ†æçµæœä¹Ÿé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚é™ä½äº†æŸäº›å…ç–«ç´°èƒçš„æ´»åŒ–ç¨‹åº¦ï¼Œé€™äº›çµæœè¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨å¥½è™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚äº†è§£é€™äº›ç‰¹æ€§å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å™¨å®˜ç§»æ¤çš„æˆåŠŸç‡ï¼Œä¸¦ç‚ºæœªä¾†çš„å¥åº·ç®¡ç†æä¾›æ–°çš„æ€è·¯ï¼Œç‰¹åˆ¥æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„ç—…äººä¸­ï¼Œå¦‚ä½•æ¸›å°‘æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œé€²è€Œæé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ï¼Œä¸¦ä¸”æ¢ç´¢å°‡å…¶èˆ‡ç†±æ•èšåˆç‰©æ°´å‡è† çµåˆçš„æ–¹å¼ï¼Œä»¥æé«˜å…¶ç™‚æ•ˆå’Œå¯ç”¨æ€§ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæ”¹å–„ç§»æ¤æ‰‹è¡“å¾Œçš„ç—…äººé å¾Œæä¾›æ–°çš„æ–¹æ³•ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œç‰¹åˆ¥æ˜¯å°‡ä¾›é«”çš„çš®è†šå¾Balb/cå°é¼ ç§»æ¤åˆ°C57BL/6å°é¼ èº«ä¸Šã€‚ç‚ºäº†æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œä»–å€‘é–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†ç›¸é—œçš„ç´°èƒæ¯’æ€§æ¸¬è©¦ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒè™•ç†çµ„åˆ¥çš„ç§»æ¤çµæœï¼Œä¸¦åˆ†æäº†å…ç–«ç´°èƒçš„æ´»åŒ–æƒ…æ³ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ ï¼Œå…¶ç§»æ¤çš®è†šçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ä»¥ä¸Šï¼Œä¸¦ä¸”åœ¨14å¤©å…§ä¿æŒè‰¯å¥½ç‹€æ…‹ã€‚èˆ‡æœªè™•ç†çš„å°é¼ ç›¸æ¯”ï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨çš®è†šçµ„ç¹”ä¸­ç™¼ç¾è¼ƒä½çš„ç™¼ç‚ç´°èƒæ•¸é‡ï¼Œé¡¯ç¤ºå‡ºå…ç–«åæ‡‰çš„æ¸›å°‘ã€‚æ­¤å¤–ï¼Œæµå¼ç´°èƒå„€çš„åˆ†æçµæœä¹Ÿé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚é™ä½äº†æŸäº›å…ç–«ç´°èƒçš„æ´»åŒ–ç¨‹åº¦ï¼Œé€™äº›çµæœè¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢å¯èƒ½è—è‘—å¹«åŠ©å™¨å®˜ç§»æ¤çš„ç§˜å¯†ï¼åœ¨å™¨å®˜ç§»æ¤ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„æŒ‘æˆ°ï¼Œé€™æœƒå½±éŸ¿åˆ°ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå¯èƒ½å°æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«ç³»çµ±æœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼çœ‹çœ‹è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ€¥æ€§æ’æ–¥åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤çš„å¯¦é©—ä¸­ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†å°é¼ ï¼Œä¸¦é–‹ç™¼äº†ä¸€ç¨®å«æœ‰è˜¿è””ç¡«ç´ çš„æ°´å‡è† ï¼Œä¾†æ¸¬è©¦å®ƒçš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ ï¼Œç§»æ¤çš®è†šçš„å­˜æ´»ç‡é”åˆ°äº†80%ä»¥ä¸Šï¼Œä¸”åœ¨14å¤©å…§ä¿æŒè‰¯å¥½ç‹€æ…‹ï¼\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘æ’æ–¥åæ‡‰æ–¹é¢çš„æ½›åŠ›ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ã€‚  \n2. æ¸›å°‘ç™¼ç‚ç´°èƒçš„æ•¸é‡ï¼Œé¡¯ç¤ºå…ç–«åæ‡‰æ¸›å°‘ã€‚  \n3. éœ€è¦é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºå®šå…¶å…·é«”ä½œç”¨ã€‚  \nä¸€èµ·æœŸå¾…æœªä¾†çš„å¥åº·ç®¡ç†æ–°æ–¹å‘å§ï¼",
    "image_prompt": "Create a flat design infographic on the effects of sulforaphane from radishes on acute rejection in organ transplants. Include simplified illustrations of radishes or broccoli, mice as experimental subjects, and arrows or flow lines to represent the experimental process. Highlight a section labeled 'Key Findings' that shows protective effects and results like improved skin graft survival rates and reduced inflammation. Use a light background with soft colors for a scientific and educational feel.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½åœ¨å¥åº·å’Œç–¾ç—…é é˜²æ–¹é¢çš„æ½›åŠ›ã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°æ‡‰å°ç™Œç—‡ç­‰é‡å¤§ç–¾ç—…ã€‚",
    "para2": "é€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ§åˆ¶è…«ç˜¤ç”Ÿé•·ã€è½‰ç§»ä»¥åŠç´°èƒå‡‹äº¡ç­‰æ–¹é¢çš„æ½›åœ¨ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡æ²»ç™‚ä¸­éå¸¸é‡è¦çš„è­°é¡Œã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€ç´°èƒé€±æœŸèª¿æ§è›‹ç™½ç­‰ã€‚ç ”ç©¶è€…ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›éƒ½æ˜¯åœ¨ç™Œç—‡æ²»ç™‚ä¸­å¯èƒ½æå‡æ•ˆæœçš„å› ç´ ã€‚é€™æ¨£çš„ç ”ç©¶æ–¹æ³•è®“æˆ‘å€‘èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸Šå…·æœ‰æ½›åœ¨çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¿ƒé€²ç´°èƒå‡‹äº¡å’ŒæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ç­‰ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æœ‰å…¶æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œå®‰å…¨æ€§ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„è¦–è§’ï¼Œä½†ä¸¦ä¸èƒ½ä¿è­‰è˜¿è””ç¡«ç´ ä¸€å®šèƒ½æ²»ç™’ç™Œç—‡ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½åœ¨å¥åº·å’Œç–¾ç—…é é˜²æ–¹é¢çš„æ½›åŠ›ã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°æ‡‰å°ç™Œç—‡ç­‰é‡å¤§ç–¾ç—…ã€‚\n\né€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ§åˆ¶è…«ç˜¤ç”Ÿé•·ã€è½‰ç§»ä»¥åŠç´°èƒå‡‹äº¡ç­‰æ–¹é¢çš„æ½›åœ¨ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡æ²»ç™‚ä¸­éå¸¸é‡è¦çš„è­°é¡Œã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€ç´°èƒé€±æœŸèª¿æ§è›‹ç™½ç­‰ã€‚ç ”ç©¶è€…ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›éƒ½æ˜¯åœ¨ç™Œç—‡æ²»ç™‚ä¸­å¯èƒ½æå‡æ•ˆæœçš„å› ç´ ã€‚é€™æ¨£çš„ç ”ç©¶æ–¹æ³•è®“æˆ‘å€‘èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸Šå…·æœ‰æ½›åœ¨çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¿ƒé€²ç´°èƒå‡‹äº¡å’ŒæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ç­‰ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æœ‰å…¶æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œå®‰å…¨æ€§ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„è¦–è§’ï¼Œä½†ä¸¦ä¸èƒ½ä¿è­‰è˜¿è””ç¡«ç´ ä¸€å®šèƒ½æ²»ç™’ç™Œç—‡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘å¼•èµ·äº†ç§‘å­¸å®¶çš„æ³¨æ„ï¼é€™ç¨®åŒ–åˆç‰©ä¸åƒ…è®“è”¬èœæ›´æœ‰ç‡Ÿé¤Šï¼Œé‚„å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸­ç™¼æ®é‡è¦è§’è‰²ã€‚  \n  \né€™ç¯‡ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚ç ”ç©¶è€…å€‘åˆ†æäº†å®ƒå¦‚ä½•èˆ‡ç™Œç´°èƒè£¡çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ§åˆ¶è…«ç˜¤ç”Ÿé•·å’Œä¿ƒé€²ç´°èƒå‡‹äº¡ï¼ˆä¹Ÿå°±æ˜¯è®“ä¸å¥åº·çš„ç´°èƒè‡ªæˆ‘æ¶ˆäº¡ï¼‰æ–¹é¢çš„æ½›åŠ›ã€‚  \n  \né€™é …ç ”ç©¶æ˜¯é€éæ–‡ç»å›é¡§é€²è¡Œçš„ï¼Œç ”ç©¶è€…å€‘æª¢è¦–äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œä¸¦æ¢è¨äº†å®ƒèˆ‡ç´ç±³æŠ€è¡“çš„å”åŒæ•ˆæ‡‰ã€‚é€™æ¨£çš„æ–¹å¼è®“æˆ‘å€‘æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚  \n  \nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸Šæœ‰æ½›åœ¨çš„å½±éŸ¿ï¼Œé›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºå®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä½†é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœå’Œå®‰å…¨æ€§ã€‚  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ§åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚  \n2. å®ƒä¿ƒé€²ç´°èƒå‡‹äº¡ï¼Œæœ‰åŠ©æ–¼æ¸…é™¤ä¸å¥åº·ç´°èƒã€‚  \n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "image_prompt": "Create a flat-design infographic on a light background that explains the experimental approach and main findings of a study on sulforaphane from broccoli. Include simplified icons representing broccoli and sulforaphane, as well as simplified figures of cells or animals as experimental subjects. Use arrows or flow lines to show the experimental steps, and include a section labeled 'Main Findings' that highlights protective effects and changes observed in cancer cells.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œéå»å·²çŸ¥å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™æ¬¡çš„ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„æ½›åœ¨ç™‚æ•ˆï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ¸›å°‘ç—‡ç‹€æœ‰ä¸€å®šçš„æ„ç¾©ã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„æ•ˆæœæœ‰é™ï¼Œä½†å®ƒä»ç„¶å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸æ–¹é¢ï¼Œé€™å°æ–¼ç²¾ç¥å¥åº·çš„ç¶­è­·æ˜¯å€¼å¾—é—œæ³¨çš„ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ•ˆæœã€‚ç ”ç©¶è€…é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–å€‹é‡å°é€™ä¸€ä¸»é¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œæ¶µè“‹äº†å¾æ–‡ç»é–‹å§‹åˆ°2025å¹´4æœˆçš„ç›¸é—œç ”ç©¶ï¼Œç‰¹åˆ¥é—œæ³¨éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ç´å…¥äº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™é …ç ”ç©¶ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™æ˜¯æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨çš„è®ŠåŒ–ï¼Œæ­¤å¤–é‚„åŒ…æ‹¬èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™äº›ç ”ç©¶çš„è·Ÿé€²æ™‚é–“ç¯„åœå¾24é€±åˆ°18é€±ï¼Œä¸¦åœ¨ä¸€è‡´çš„12é€±æ™‚é–“é»é€²è¡Œè©•ä¼°ï¼Œä»¥ç¢ºä¿çµæœçš„å¯é æ€§ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†æˆ–æ­£æ€§ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„è©•ä¼°ä¸­ï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰æ­£é¢å½±éŸ¿ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œéå»å·²çŸ¥å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™æ¬¡çš„ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„æ½›åœ¨ç™‚æ•ˆï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ¸›å°‘ç—‡ç‹€æœ‰ä¸€å®šçš„æ„ç¾©ã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ çš„æ•ˆæœæœ‰é™ï¼Œä½†å®ƒä»ç„¶å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸æ–¹é¢ï¼Œé€™å°æ–¼ç²¾ç¥å¥åº·çš„ç¶­è­·æ˜¯å€¼å¾—é—œæ³¨çš„ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ•ˆæœã€‚ç ”ç©¶è€…é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–å€‹é‡å°é€™ä¸€ä¸»é¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œæ¶µè“‹äº†å¾æ–‡ç»é–‹å§‹åˆ°2025å¹´4æœˆçš„ç›¸é—œç ”ç©¶ï¼Œç‰¹åˆ¥é—œæ³¨éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ç´å…¥äº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡äº†é€™é …ç ”ç©¶ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™æ˜¯æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨çš„è®ŠåŒ–ï¼Œæ­¤å¤–é‚„åŒ…æ‹¬èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™äº›ç ”ç©¶çš„è·Ÿé€²æ™‚é–“ç¯„åœå¾24é€±åˆ°18é€±ï¼Œä¸¦åœ¨ä¸€è‡´çš„12é€±æ™‚é–“é»é€²è¡Œè©•ä¼°ï¼Œä»¥ç¢ºä¿çµæœçš„å¯é æ€§ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†æˆ–æ­£æ€§ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„è©•ä¼°ä¸­ï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰æ­£é¢å½±éŸ¿ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“è˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯ä¸æ˜¯ä»€éº¼ç¥å¥‡è—¥ç‰©ï¼Œè€Œæ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„å¤©ç„¶æˆåˆ†ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å®ƒå°ç²¾ç¥åˆ†è£‚ç—‡çš„å½±éŸ¿ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹é€™é …ç ”ç©¶çš„ç™¼ç¾å§ï¼\n\nç ”ç©¶è€…å€‘é€²è¡Œäº†ä¸€å€‹ç³»çµ±æ€§çš„å›é¡§ï¼Œåˆ†æäº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æœ‰369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡ã€‚ä»–å€‘ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°æ‚£è€…ç—‡ç‹€çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯æ­£è² ç—‡ç‹€çš„è®ŠåŒ–ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„æŸäº›ç—‡ç‹€ä¸Šå¯èƒ½æœ‰è¼•å¾®çš„å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯åœ¨è² æ€§ç—‡ç‹€æ–¹é¢æœ‰äº›æ”¹å–„ã€‚æ­¤å¤–ï¼Œé€™é …ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ä¸€äº›ä¸å¥åº·çš„ä»£è¬æ¨™è¨˜ï¼Œå¦‚è†½å›ºé†‡å’Œä¸‰é…¸ç”˜æ²¹è„‚ï¼Œé€™å°å¿ƒè¡€ç®¡å¥åº·ä¹Ÿæ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\nä¸éï¼Œé€™äº›çµæœé‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªï¼Œå› ç‚ºç›®å‰çš„æ•¸æ“šé‚„æœ‰é™ã€‚ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç²¾ç¥ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚\n2. å®ƒèƒ½é™ä½ä¸€äº›ä¸å¥åº·çš„ä»£è¬æŒ‡æ¨™ã€‚\n3. ä»éœ€æ›´å¤šç ”ç©¶ä¾†é€²ä¸€æ­¥äº†è§£å®ƒçš„æ•ˆæœã€‚ \nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒç²¾ç¥å¥åº·ï¼Œä¿æŒå¥åº·çš„ç”Ÿæ´»æ–¹å¼ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or sulforaphane. Simplified illustrations of experiment subjects like people or cells. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed. Use soft colors and a clear, educational style.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å¯èƒ½çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„æƒ…æ³ä¸‹ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®æœƒå½±éŸ¿å­•å©¦å’Œèƒå…’å¥åº·çš„ç–¾ç—…ï¼Œå¯èƒ½å°è‡´æ¯é«”å™¨å®˜åŠŸèƒ½éšœç¤™å’Œèƒå…’ç”Ÿé•·å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æœ‰å®³å½±éŸ¿ï¼Œå¾è€Œå°æŠ—å¦Šå¨ é«˜è¡€å£“ç—‡çš„è² é¢å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ½›åœ¨çš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„å­•å©¦å’Œèƒå…’çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¯¦é©—å®¤ç’°å¢ƒä¸­é¡¯ç¤ºå‡ºä¿è­·å…§çš®ç´°èƒçš„èƒ½åŠ›ï¼Œä½†åœ¨å¯¦éš›çš„å¦Šå¨ æƒ…æ³ä¸‹ï¼Œé€™ç¨®ç‰©è³ªæ˜¯å¦èƒ½å¤ æœ‰æ•ˆåœ°è½‰ç§»åˆ°èƒå…’èº«ä¸Šï¼Œä¸¦å°èƒå…’ç”¢ç”Ÿå½±éŸ¿ã€‚",
    "para3": "å¯¦é©—çš„å°è±¡æ˜¯å…«ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚æä¾›äº†æ›¸é¢åŒæ„ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆå¥¹å€‘ä¸€æ¬¡å£æœçš„è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆEnduraCellï¼‰ï¼Œç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚æ‰‹è¡“å‰ï¼Œç ”ç©¶è€…æ”¶é›†äº†å­•å©¦çš„åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2åˆ°4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨ä¸€æ¬¡è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€å¢åŠ ï¼Œä½†åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿é–‹å•Ÿäº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å¯èƒ½çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„æƒ…æ³ä¸‹ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®æœƒå½±éŸ¿å­•å©¦å’Œèƒå…’å¥åº·çš„ç–¾ç—…ï¼Œå¯èƒ½å°è‡´æ¯é«”å™¨å®˜åŠŸèƒ½éšœç¤™å’Œèƒå…’ç”Ÿé•·å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æœ‰å®³å½±éŸ¿ï¼Œå¾è€Œå°æŠ—å¦Šå¨ é«˜è¡€å£“ç—‡çš„è² é¢å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ½›åœ¨çš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„å­•å©¦å’Œèƒå…’çš„å¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¯¦é©—å®¤ç’°å¢ƒä¸­é¡¯ç¤ºå‡ºä¿è­·å…§çš®ç´°èƒçš„èƒ½åŠ›ï¼Œä½†åœ¨å¯¦éš›çš„å¦Šå¨ æƒ…æ³ä¸‹ï¼Œé€™ç¨®ç‰©è³ªæ˜¯å¦èƒ½å¤ æœ‰æ•ˆåœ°è½‰ç§»åˆ°èƒå…’èº«ä¸Šï¼Œä¸¦å°èƒå…’ç”¢ç”Ÿå½±éŸ¿ã€‚\n\nå¯¦é©—çš„å°è±¡æ˜¯å…«ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚æä¾›äº†æ›¸é¢åŒæ„ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆå¥¹å€‘ä¸€æ¬¡å£æœçš„è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆEnduraCellï¼‰ï¼Œç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚æ‰‹è¡“å‰ï¼Œç ”ç©¶è€…æ”¶é›†äº†å­•å©¦çš„åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2åˆ°4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨ä¸€æ¬¡è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€å¢åŠ ï¼Œä½†åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿é–‹å•Ÿäº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå¯èƒ½å°å­•å©¦å’Œèƒå…’çš„å¥åº·æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿å­•å©¦å’Œèƒå…’å¥åº·çš„ç–¾ç—…ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œé€™ç¨®åœ¨å¯¦é©—å®¤ä¸­é¡¯ç¤ºå‡ºä¿è­·å…§çš®ç´°èƒçš„ç‰©è³ªï¼Œæ˜¯å¦èƒ½åœ¨å¦Šå¨ æœŸé–“æœ‰æ•ˆåœ°è½‰ç§»åˆ°èƒå…’èº«ä¸Šã€‚  \n  \nç‚ºäº†é€²è¡Œé€™é …ç ”ç©¶ï¼Œå…«ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å­•å©¦åƒåŠ äº†å¯¦é©—ã€‚å¥¹å€‘åœ¨æ‰‹è¡“å‰æœç”¨äº†è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“éç¨‹ä¸­æ”¶é›†äº†å¥¹å€‘çš„è¡€æ¶²å’Œèƒç›¤æ¨£æœ¬ã€‚ç ”ç©¶è€…ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€å’Œæ¯ä¹³ä¸­éƒ½æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦å®ƒèƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šï¼é›–ç„¶åœ¨æ‰‹è¡“ç•¶å¤©ï¼Œå­•å©¦çš„è¡€å£“æœ‰äº›è®ŠåŒ–ï¼Œä½†ç¸½é«”ä¾†èªªï¼Œé€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿é–‹å•Ÿäº†æ–°çš„æ–¹å‘ã€‚  \n  \nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¦Šå¨ é«˜è¡€å£“ç—‡çš„å½±éŸ¿ã€‚  \n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚  \n3. é€™äº›çµæœç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains a research study on sulforaphane, a compound found in broccoli, and its effects on pregnancy. Include simple icons of broccoli and sulforaphane, a simplified representation of pregnant women as study subjects, and arrows showing the experimental steps. Add a section labeled 'Main Findings' that highlights key results such as the detection of sulforaphane in maternal serum, umbilical cord blood, and breast milk, indicating its transfer from mother to fetus.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸æœƒå‡ºç¾ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œèƒ½å¤ å•Ÿå‹•Nrf2é€šè·¯ï¼Œæ¸›å°‘ç·šç²’é«”ä¸­çš„ROSï¼Œé€™å°æ–¼æ¸›è¼•å¿ƒè‡Ÿæå‚·å’Œæ”¹å–„å¿ƒè¡€ç®¡å¥åº·å¯èƒ½æœ‰å¹«åŠ©ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æ¸›å°‘å†çŒæ³¨æå‚·æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯å¦‚ä½•æ”¹å–„æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æå‚·å•é¡Œã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éåˆæˆæ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ä¾†æé«˜å…¶ç©©å®šæ€§å’Œæ²»ç™‚æ•ˆæœï¼Œå¾è€Œæ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒåœ¨ç¼ºæ°§å†çŒæ³¨éç¨‹ä¸­å—åˆ°çš„æå‚·ã€‚é€™äº›è¡ç”Ÿç‰©çš„è¨­è¨ˆæ˜¯åŸºæ–¼å…¶åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚æ–¹é¢çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè¡€ç®¡ç–¾ç—…ç›¸é—œçš„æ°§åŒ–å£“åŠ›å•é¡Œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®æ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦å°å…¶é€²è¡Œäº†å¤šé …æ¸¬è©¦ã€‚é€™äº›æ¸¬è©¦åŒ…æ‹¬è©•ä¼°å…¶å°å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒçš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶æŠ—è…«ç˜¤æ´»æ€§ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§ï¼Œä¸¦ç¢ºå®šå…¶åœ¨Nrf2/Keap1é€šè·¯ä¸­çš„ä½œç”¨ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•åœ¨ç”Ÿç‰©é«”å…§ç™¼æ®ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘ROSæ°´å¹³å’Œå¢åŠ ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨æŠ—å¢æ®–æ´»æ€§ä¸Šæ¯”å‚³çµ±è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å…·æ•ˆåŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gåœ¨æ¸›è¼•ç¼ºè¡€å†çŒæ³¨æå‚·å’Œç›¸é—œçš„æ°§åŒ–å£“åŠ›æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œä¸¦ä¸”å…¶ç©©å®šæ€§åœ¨ä¸åŒæº¶åŠ‘ä¸­ä¹Ÿå¾—åˆ°äº†å¢å¼·ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†é‡å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æœ‰æ•ˆæ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸æœƒå‡ºç¾ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œèƒ½å¤ å•Ÿå‹•Nrf2é€šè·¯ï¼Œæ¸›å°‘ç·šç²’é«”ä¸­çš„ROSï¼Œé€™å°æ–¼æ¸›è¼•å¿ƒè‡Ÿæå‚·å’Œæ”¹å–„å¿ƒè¡€ç®¡å¥åº·å¯èƒ½æœ‰å¹«åŠ©ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æ¸›å°‘å†çŒæ³¨æå‚·æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯å¦‚ä½•æ”¹å–„æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æå‚·å•é¡Œã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éåˆæˆæ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ä¾†æé«˜å…¶ç©©å®šæ€§å’Œæ²»ç™‚æ•ˆæœï¼Œå¾è€Œæ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒåœ¨ç¼ºæ°§å†çŒæ³¨éç¨‹ä¸­å—åˆ°çš„æå‚·ã€‚é€™äº›è¡ç”Ÿç‰©çš„è¨­è¨ˆæ˜¯åŸºæ–¼å…¶åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚æ–¹é¢çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè¡€ç®¡ç–¾ç—…ç›¸é—œçš„æ°§åŒ–å£“åŠ›å•é¡Œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®æ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦å°å…¶é€²è¡Œäº†å¤šé …æ¸¬è©¦ã€‚é€™äº›æ¸¬è©¦åŒ…æ‹¬è©•ä¼°å…¶å°å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒçš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶æŠ—è…«ç˜¤æ´»æ€§ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§ï¼Œä¸¦ç¢ºå®šå…¶åœ¨Nrf2/Keap1é€šè·¯ä¸­çš„ä½œç”¨ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•åœ¨ç”Ÿç‰©é«”å…§ç™¼æ®ä½œç”¨ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘ROSæ°´å¹³å’Œå¢åŠ ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨æŠ—å¢æ®–æ´»æ€§ä¸Šæ¯”å‚³çµ±è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å…·æ•ˆåŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gåœ¨æ¸›è¼•ç¼ºè¡€å†çŒæ³¨æå‚·å’Œç›¸é—œçš„æ°§åŒ–å£“åŠ›æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œä¸¦ä¸”å…¶ç©©å®šæ€§åœ¨ä¸åŒæº¶åŠ‘ä¸­ä¹Ÿå¾—åˆ°äº†å¢å¼·ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†é‡å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶è‡¨åºŠæ‡‰ç”¨çš„æœ‰æ•ˆæ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿåœ¨é¢å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡æ™‚ï¼Œæœƒç¶“æ­·ä¸€å ´å°å°çš„æˆ°çˆ­ï¼é€™ç¯‡ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡æ‚£è€…åœ¨æ¥å—æ²»ç™‚å¾Œï¼Œå¸¸å¸¸æœƒå—åˆ°ä¸€ç¨®å«åšç¼ºè¡€å†çŒæ³¨æå‚·çš„å½±éŸ¿ï¼Œé€™å’Œéå¤šçš„æ´»æ€§æ°§æœ‰é—œã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æˆåˆ†ï¼Œèƒ½å¹«åŠ©æ¸›å°‘é€™äº›æœ‰å®³ç‰©è³ªï¼Œå¾è€Œä¿è­·å¿ƒè‡Ÿï¼\n\nä»–å€‘çš„ç ”ç©¶é‡é»æ˜¯å¦‚ä½•æ”¹å–„å¿ƒè‡Ÿåœ¨ç¼ºæ°§å¾Œçš„æ¢å¾©æƒ…æ³ã€‚é€éåˆæˆæ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½è®“é€™äº›æˆåˆ†åœ¨æ²»ç™‚ä¸Šæ›´æœ‰æ•ˆã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘æ¸¬è©¦äº†å¹¾ç¨®æ–°çš„åŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦ç™¼ç¾å®ƒèƒ½é¡¯è‘—æ¸›å°‘æœ‰å®³çš„æ´»æ€§æ°§ï¼Œé‚„èƒ½ä¿ƒé€²ä¸€æ°§åŒ–æ°®çš„ç”Ÿæˆï¼Œé€™å°å¿ƒè‡Ÿå¥åº·éå¸¸é‡è¦ï¼\n\né€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿæå‚·ã€‚\n2. åŒ–åˆç‰©3gåœ¨æŠ—æ°§åŒ–å’Œä¿è­·å¿ƒè‡Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ã€‚\n3. é€™äº›ç™¼ç¾å¯èƒ½ç‚ºå¿ƒè¡€ç®¡ç–¾ç—…çš„æœªä¾†æ²»ç™‚æä¾›æ–°æ–¹å‘ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªï¼",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of a study on a compound derived from sulforaphane. Include simplified icons representing broccoli or sulforaphane, experimental subjects like humans or cells, arrows or flow lines to indicate experimental steps, and a section clearly labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œå› ç‚ºå®ƒå€‘é¡¯ç¤ºäº†æŸäº›å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªåœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ°§åŒ–æå‚·ï¼Œé€²è€Œä¿è­·ç´°èƒå’Œçµ„ç¹”çš„å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å°æ¯”äº†å…©ç¨®åŒ–åˆç‰©ï¼šè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å’Œå¦ä¸€ç¨®åç‚ºesculinï¼ˆESCï¼‰çš„åŒ–åˆç‰©ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­ï¼Œé€™å€‹å› å­åœ¨å°æŠ—æ°§åŒ–æå‚·ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚",
    "para3": "å¯¦é©—ä½¿ç”¨äº†æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç”Ÿç‰©é†«å­¸ç ”ç©¶çš„æ¨¡å‹ç”Ÿç‰©ã€‚ç ”ç©¶è€…å°‡æ–‘é¦¬é­šå¹¼é«”åˆ†ç‚ºå¹¾çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œä¸¦é€²è¡Œäº†6å°æ™‚çš„è™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼Œå¦‚ROSã€è„‚è³ªéæ°§åŒ–ã€æ°®æ°§åŒ–ç‰©ç­‰ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†è©•ä¼°æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨ç¾ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­é‚„ç™¼ç¾ï¼ŒNrf2åœ¨è™•ç†å¾Œè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ï¼Œé€™è¡¨æ˜å®ƒåœ¨ç´°èƒå…§çš„æ´»æ€§å¾—åˆ°äº†å¢å¼·ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼çš„æŠ—æ°§åŒ–ä½œç”¨ï¼Œä¸¦å¯èƒ½é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œå› ç‚ºå®ƒå€‘é¡¯ç¤ºäº†æŸäº›å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªåœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ°§åŒ–æå‚·ï¼Œé€²è€Œä¿è­·ç´°èƒå’Œçµ„ç¹”çš„å¥åº·ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å°æ¯”äº†å…©ç¨®åŒ–åˆç‰©ï¼šè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å’Œå¦ä¸€ç¨®åç‚ºesculinï¼ˆESCï¼‰çš„åŒ–åˆç‰©ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­ï¼Œé€™å€‹å› å­åœ¨å°æŠ—æ°§åŒ–æå‚·ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚\n\nå¯¦é©—ä½¿ç”¨äº†æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç”Ÿç‰©é†«å­¸ç ”ç©¶çš„æ¨¡å‹ç”Ÿç‰©ã€‚ç ”ç©¶è€…å°‡æ–‘é¦¬é­šå¹¼é«”åˆ†ç‚ºå¹¾çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œä¸¦é€²è¡Œäº†6å°æ™‚çš„è™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼Œå¦‚ROSã€è„‚è³ªéæ°§åŒ–ã€æ°®æ°§åŒ–ç‰©ç­‰ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†è©•ä¼°æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨ç¾ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­é‚„ç™¼ç¾ï¼ŒNrf2åœ¨è™•ç†å¾Œè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ï¼Œé€™è¡¨æ˜å®ƒåœ¨ç´°èƒå…§çš„æ´»æ€§å¾—åˆ°äº†å¢å¼·ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼çš„æŠ—æ°§åŒ–ä½œç”¨ï¼Œä¸¦å¯èƒ½é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€äº›ç¥ç§˜çš„è‹±é›„ï¼Œå°ˆé–€å°æŠ—é‚£äº›å¯æ€•çš„è‡ªç”±åŸºï¼é€™ç¯‡ç ”ç©¶å°±å‘Šè¨´æˆ‘å€‘ï¼ŒæŸäº›å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ï¼Œåœ¨é€™æ–¹é¢çœŸæ˜¯äº†ä¸èµ·ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®å«åšesculinçš„åŒ–åˆç‰©ï¼Œæƒ³çœ‹çœ‹å®ƒå€‘å¦‚ä½•å½±éŸ¿ä¸€å€‹å«åšNrf2çš„è½‰éŒ„å› å­ã€‚é€™å€‹å› å­å°±åƒæ˜¯ç´°èƒçš„å®ˆè­·è€…ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–æå‚·ã€‚\n\nç ”ç©¶è€…å€‘ä½¿ç”¨æ–‘é¦¬é­šå¹¼é«”ä¾†é€²è¡Œå¯¦é©—ï¼Œåˆ†æˆå¹¾çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒçš„è™•ç†ï¼Œåƒæ˜¯100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„åæ‡‰ã€‚ä»–å€‘æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼Œåƒæ˜¯è‡ªç”±åŸºå’ŒæŠ—æ°§åŒ–åŸºå› çš„è¡¨ç¾ã€‚\n\nçµæœé¡¯ç¤ºï¼Œesculinçš„æ•ˆæœè·Ÿè˜¿è””ç¡«ç´ ç›¸ä¼¼ï¼Œèƒ½é¡¯è‘—æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé‚„ä¿ƒé€²äº†æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ã€‚é€™æ„å‘³è‘—esculinä¹Ÿèƒ½å¹«åŠ©ä¿è­·ç´°èƒï¼Œè®“æˆ‘å€‘çš„èº«é«”æ›´å¥åº·ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å’Œesculinéƒ½æ˜¯å¤©ç„¶çš„æŠ—æ°§åŒ–åŠ‘ã€‚\n2. Nrf2æ˜¯ç´°èƒå…§çš„æŠ—æ°§åŒ–å®ˆè­·è€…ã€‚\n3. é€™äº›åŒ–åˆç‰©èƒ½æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œå¹«åŠ©ä¿è­·ç´°èƒï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include simple icons representing broccoli or sulforaphane. Show simplified representations of experimental subjects like fish or cells. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œä½¿ç”¨ä¸Šé¢è‡¨æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚ç–¾ç—…çš„æ²»ç™‚ä¸Šã€‚é€éæ”¹è‰¯è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œæˆ–è¨±èƒ½æ›´æœ‰æ•ˆåœ°ç™¼æ®å…¶æ½›åœ¨çš„å¥åº·æ•ˆç›Šï¼Œé€²è€Œæ”¹å–„ç›¸é—œç–¾ç—…çš„æ²»ç™‚æ•ˆæœã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£èª˜å°çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„çµåˆç‰©ï¼Œæå‡è˜¿è””ç¡«ç´ åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ²»ç™‚æ½›åŠ›ã€‚é€™å€‹å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§è„‚å¤šé†£ç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç™¼ç‚æƒ…æ³ã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§é€²è¡Œæ¸¬è©¦ã€‚é€™äº›çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£æ€§å’Œç”Ÿç‰©å¯åˆ©ç”¨æ€§ï¼Œå…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œä¸»è¦æ˜¯é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿé€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›çµåˆç‰©èƒ½èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•æä¾›äº†å»£æ³›çš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œä½¿ç”¨ä¸Šé¢è‡¨æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚ç–¾ç—…çš„æ²»ç™‚ä¸Šã€‚é€éæ”¹è‰¯è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œæˆ–è¨±èƒ½æ›´æœ‰æ•ˆåœ°ç™¼æ®å…¶æ½›åœ¨çš„å¥åº·æ•ˆç›Šï¼Œé€²è€Œæ”¹å–„ç›¸é—œç–¾ç—…çš„æ²»ç™‚æ•ˆæœã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©å°æ–¼ç”±è„‚å¤šé†£èª˜å°çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„çµåˆç‰©ï¼Œæå‡è˜¿è””ç¡«ç´ åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ²»ç™‚æ½›åŠ›ã€‚é€™å€‹å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ–¹å‘ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§è„‚å¤šé†£ç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç™¼ç‚æƒ…æ³ã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§é€²è¡Œæ¸¬è©¦ã€‚é€™äº›çµåˆç‰©çš„è¨­è¨ˆæ—¨åœ¨æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£æ€§å’Œç”Ÿç‰©å¯åˆ©ç”¨æ€§ï¼Œå…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œä¸»è¦æ˜¯é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿé€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›çµåˆç‰©èƒ½èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•æä¾›äº†å»£æ³›çš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œå°å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼ä¸éï¼Œç”±æ–¼å®ƒä¸å®¹æ˜“è¢«èº«é«”å¸æ”¶ï¼Œé€™è®“æˆ‘å€‘åœ¨åˆ©ç”¨å®ƒçš„æ™‚å€™é‡åˆ°äº†ä¸€äº›æŒ‘æˆ°ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨äº†å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œè®“å®ƒèƒ½æ›´æœ‰æ•ˆåœ°å¹«åŠ©æˆ‘å€‘å°æŠ—ç™¼ç‚ç–¾ç—…ï¼\n\né€™é …ç ”ç©¶çš„åœ˜éšŠï¼Œä½¿ç”¨äº†å¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œæ¨¡æ“¬ç™¼ç‚çš„ç’°å¢ƒï¼Œä¸¦é–‹ç™¼äº†ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ã€‚ä»–å€‘æ¸¬è©¦äº†é€™äº›çµåˆç‰©åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢çš„æ•ˆæœï¼Œçµæœç™¼ç¾é€™äº›æ–°å‹çµåˆç‰©ä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œé‚„èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·ï¼\n\né€™é …ç ”ç©¶çš„é‡é»åŒ…æ‹¬ï¼š\n- è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©èƒ½é¡¯è‘—æŠ‘åˆ¶ç™¼ç‚åæ‡‰ã€‚\n- å®ƒå€‘é€šéç‰¹å®šçš„é€”å¾‘ä¾†ç™¼æ®ä½œç”¨ï¼Œä¸¦ä¸å½±éŸ¿å…¶ä»–é‡è¦çš„ä¿¡è™Ÿé€šè·¯ã€‚\n- é€™äº›çµåˆç‰©é‚„èƒ½å¢å¼·å…ç–«ç³»çµ±çš„åŠŸèƒ½ï¼Œå°æœªä¾†çš„å¥åº·é£Ÿå“é–‹ç™¼æä¾›äº†æ–°æ–¹å‘ï¼\n\nè®“æˆ‘å€‘æœŸå¾…é€™äº›ç ”ç©¶èƒ½å¸¶ä¾†æ›´å¤šå¥åº·çš„å¯èƒ½æ€§ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on a compound called sulforaphane from radishes. Include simplified illustrations of radishes or broccoli, and cells as experimental subjects. Use arrows or flow lines to indicate the steps of the experiment. Include a section that highlights the main results, such as protective effects and immune response enhancement, on a light-colored background with soft colors.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  }
]